The Drug Situation in Norway 2008 Annual report to the European Monitoring Centre for Drugs and Drug Addiction – EMCDDA by Hordvin, Odd
SiruS  Norwegian institute for Alcohol and Drug research  
The Drug Situation in Norway 2008
Annual report to the European Monitoring Centre  
for Drugs and Drug Addiction – EMCDDA
IRU
The Drug Situation in Norway 20082
Acknowledgements 
Since 2001, SIRUS has been the Norwegian Fo-
cal Point for the European Monitoring Centre 
for Drugs and Drug Addiction - EMCDDA. All 
member countries submit an annual national re-
port and, in addition, a number of standardised 
tables, mainly epidemiological data. In 2008, two 
comprehensive questionnaires have also been 
completed, on treatment programmes and on 
prevention of health-related harm associated 
with drug use. They have been submitted sepa-
rately to the EMCDDA.
As in previous years, this 8th annual national re-
port on the drug situation in Norway has been 
drawn up in accordance with the reporting guid-
elines common to all member states in the 
EMCDDA. Since the report is intended to be 
brief and to primarily cover important develop-
ment trends, it may appear rather fragmentary. 
Little of the information provided in last year’s 
report will be repeated in this report. References 
are included instead. However, we hope that the 
report will prove useful to readers who wish to 
familiarise themselves with the drugs situation 
in Norway. SIRUS wishes to express its gratitude 
to all experts, external partners and public insti-
tutions that helped in the preparation of the re-
port. Our thanks go in particular to the co-aut-
hors who have made textual contributions and to 
the author of the selected topic.
Oslo, November 2008 
Odd Hordvin
Head of Focal Point
Annual report to the European Monitoring Centre for Drugs and Drug Addiction – EMCDDA 3
Editor:
Odd Hordvin
With the assistance of: 
Astrid Skretting and Jostein Rise, SIRUS
Co-authors:
Ministry of Health and Care Services: Chapter 1
Hege C. Lauritzen, SIRUS: Chapter 3
Directorate of Health: Chapter 3
Ellen J. Amundsen, SIRUS: Chapters 4.1 and 6.1
Einar Ødegård, SIRUS: Chapter 6.1
Hans Blystad, Norwegian Institute of Public 
Health: Chapter 6.2
Tormod Bønes, National Criminal Investigation 
Service: Chapter 10.3
Author of selected issue, Chapter 11:
Ragnar Hauge, SIRUS/University of Oslo
Translation:
Allegro Language Services, Bergen
Authors 
The Drug Situation in Norway 20084
Contents
Acknowledgements  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 2
Authors  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 3
Summary .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 6
PART A: New developments and trends  .  .  .  .  . 9
1 . National policies and context  .  .  .  .  .  .  .  .  .  .  . 10
 1.1 Legal framework . . . . . . . . . . . . . . . . . . 10
 1.2  Institutional framework,  
strategies and policies . . . . . . . . . . . . . 10
 1.2.1  Norwegian National Action Plan  
on Alcohol and Drugs. . . . . . . . . . . . . 11
 1.2.2 New research centre . . . . . . . . . . . . . 12
 1.3  Budget and public expenditure . . . . . . 12
 1.4 Social and cultural context . . . . . . . . . . 14
2 . Drug use in the population  .  .  .  .  .  .  .  .  .  .  .  .  . 15
 2.1  Drug use in the general population . . . 15
 2.2  Drug use in the school and youth  
population . . . . . . . . . . . . . . . . . . . . . . . 15
 2.2.1 Drug use among youth aged 15–20. . 15
 2.2.2 Hash use among young adults . . . . . 17
 2.3  Drug use among specific groups . . . . . 18
 2.3.1.  Drug use among persons from  
immigrant backgrounds . . . . . . . . . . 18
3 . Prevention .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 22
 3.1 Universal prevention . . . . . . . . . . . . . . . 22
 3.2 Selective prevention . . . . . . . . . . . . . . . 23
 3.3 Indicated prevention . . . . . . . . . . . . . . . 24
 3.3.1 Early intervention . . . . . . . . . . . . . . . . 24
4 .  Problem drug use and the  
treatment population .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 25
 4.1  Prevalence and incidence estimates of 
PDU . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
 4.2. Treatment demand indicator. . . . . . . . 26
 4.2.1  Profiles of clients in medically  
assisted treatment . . . . . . . . . . . . . . . 26
 4.3  PDUs from non- treatment sources . . 28
5 . Drug-related treatment  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 29
 5.1 Treatment systems . . . . . . . . . . . . . . . . 29
 5.1.1  Guide to processing referrals  
to interdisciplinary specialist  
treatment for drug and/or  
alcohol use . . . . . . . . . . . . . . . . . . . . . 29
 5.2 Drug-free treatment . . . . . . . . . . . . . . . 31
 5.3  Pharmacologically-assisted  
treatment . . . . . . . . . . . . . . . . . . . . . . . . 31
6 . Health correlates and consequences  .  .  .  . 32
 6.1  Drug-related deaths and mortality  
of drug users . . . . . . . . . . . . . . . . . . . . . 32
 6.2  Drug-related infectious diseases. . . . . 34
 6.2.1 HIV and AIDS. . . . . . . . . . . . . . . . . . . . 34
 6.2.2 Hepatitis . . . . . . . . . . . . . . . . . . . . . . . 35
 6.3 Psychiatric co-morbidity . . . . . . . . . . . . 35
7 .  Responses to health correlates and  
consequences .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 36
 7.1 Prevention of drug-related deaths. . . . 36
 7.1.1  Evaluation of the trial scheme for 
injection rooms. . . . . . . . . . . . . . . . . . 36
 7.1.2  Evaluation of low-threshold  
health services . . . . . . . . . . . . . . . . . . 38
Annual report to the European Monitoring Centre for Drugs and Drug Addiction – EMCDDA 5
PART B: Selected issue  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 55
11 . Sentencing statistics - Norway .  .  .  .  .  .  .  .  . 56
 11.1  Options available in the country –  
penal sanctions in Norway . . . . . . . . . 56
 11.1.1 The general system of sanctions . . 56
 11.1.2. Penal provisions for drug crimes. . 57
 11.1.3.  Penal provisions for driving  
under the influence of drugs . . . . . 58
 11.2. Data collection systems. . . . . . . . . . . 59
 11.2.1. Crime statistics . . . . . . . . . . . . . . . . 59
 11.3 Data collected . . . . . . . . . . . . . . . . . . . 60
 11.4 Results available . . . . . . . . . . . . . . . . . 60
 11.4.1 Statistics for drug crimes . . . . . . . . 60
 11.4.2  Statistics for driving under  
the influence of drugs . . . . . . . . . . . 61
References  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 63
Lists  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 65
 7.2  Prevention and treatment of  
drug-related infectious diseases . . . . . 39
 7.3  Interventions related to  
psychiatric co-morbidity . . . . . . . . . . . . 39
 7.3.1  National professional guidelines for 
examining, treating and following  
up persons with serious mental  
health problems and concurrent  
drug or alcohol problems. . . . . . . . . . 39
8 . Social correlates and consequences  .  .  .  .  . 41
 8.1 Social exclusion. . . . . . . . . . . . . . . . . . . 41
 8.2 Drug-related crime . . . . . . . . . . . . . . . . 41
 8.2.1 Drug offences . . . . . . . . . . . . . . . . . . . 41
 8.2.2 Driving offences . . . . . . . . . . . . . . . . . 41
 8.3 Drug use in prison. . . . . . . . . . . . . . . . . 43
 8.4 Social costs . . . . . . . . . . . . . . . . . . . . . . 44
9 .  Responses to social correlates and  
consequences .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 45
 9.1 Social re-integration . . . . . . . . . . . . . . . 45
 9.2  Prevention of drug-related crime . . . . 45
 9.2.1 Assistance to drug users in prison . . 45
10 . Drug markets  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 47
 10.1 Availability . . . . . . . . . . . . . . . . . . . . . . 47
 10.2  Production, sources of supply and 
trafficking patterns . . . . . . . . . . . . . . . 47
 10.3 Seizures . . . . . . . . . . . . . . . . . . . . . . . . 48
 10.3.1  Seizures and purity of different  
types of drugs . . . . . . . . . . . . . . . . . . 49
 10.4 Prices . . . . . . . . . . . . . . . . . . . . . . . . . . 53
The Drug Situation in Norway 20086
decline appears to be somewhat greater among 
young people in Oslo than in the country as a 
whole.
Among young adults in their twenties, the figu-
res are substantially higher, both for ever having 
used and recent use. In a survey from 2006, life-
time prevalence among the 21–30 age group had 
increased considerably in the preceding eight ye-
ars, both for cannabis and other commonly used 
drugs. However, the prevalence for recent use, 
during the past six months, has been quite stable 
overall.
The next nationwide survey among the popula-
tion as a whole is scheduled for 2009.
Injecting drug use
The trend for the number of injecting drug users 
remains largely unchanged; the figure increased 
until 2001, then fell until 2003 before levelling 
out. Summarising estimates from two methods, 
it was calculated that there were approximately 
8,500 to 12,500 injecting drug users in Norway 
in 2006.
Treatment
Data from treatment services are still only avail-
able at aggregate level. The inclusion of all ad-
missions to the interdisciplinary specialist health 
service in the Norwegian Patient Register will 
start on 1 January 2009.
A waiting list guarantee for children and young 
people entered into force on 1 September 2008. 
The waiting list guarantee is intended to ensure 
that no one who is entitled to necessary medical 
help shall have to wait for more than maximum 
65 working days for treatment, and everyone will 
be entitled to an evaluation within 10 working 
days (as opposed to 30 working days for those 
Summary
Main findings
National policies and context
A temporary Act relating to injection rooms ap-
plies until 16 December 2009. On 31 October 
2008, a consultation proposal was distributed in 
which it is proposed to make the Act permanent. 
The proposal means that it will be up to the indi-
vidual municipalities to establish injection rooms 
as part of their overall services. It is proposed to 
discontinue the state grants that were available as 
part-financing during the trial period. The Regu-
lations that have been issued will largely be con-
tinued in their present form in order to enable 
the measure to be defined as a health service.
In October 2007, the Government presented an 
action plan to the Storting (Parliament) for the 
drugs and alcohol field. It includes goals and me-
asures for prevention, treatment and rehabilita-
tion and entails a gradual escalation of funding 
in this field in the period up until 2010. The plan 
includes alcohol and drugs policy as well as na-
tional and international measures. The plan aims 
for a policy with a clear public health perspecti-
ve. The aim is to raise professional standards 
through research and by strengthening compe-
tence and quality. As regards services, the princi-
ple is that the ordinary services should also be 
available to people with drug or alcohol pro-
blems. Cooperation between the different bodies 
and administrative levels is emphasised, as is the 
user perspective.
Drug use in the population
The annual questionnaire survey among young 
people aged between 15 and 20 in 2007 shows 
that cannabis, primarily hash, is still the drug 
most young people report having used. However, 
after peaking at the turn of the millennium, a 
clear reduction has been registered in recent 
years. The proportion who state that they have 
used other drugs also increased in the late 1990s 
before stagnating/ declining in recent years. The 
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over the age of 23). In connection with the 
amendment of the law, a practice guide and a 
prioritisation guide are being issued that are in-
tended to ensure uniform, good professional 
practice in the services.
Health correlates, consequences  
and responses
In Norway, there are two bodies that register 
drug-related deaths. According to preliminary 
statistics from the National Criminal Investiga-
tion Service (Kripos) for 2007, the number of 
drug-induced deaths was 200, an increase of 5 
on 2006. Very many of the deaths are believed to 
be due to extensive polydrug use.
The most recent data from Statistics Norway are 
from 2006. They show a total of 251 drug-related 
deaths. Suicides in which narcotic substances 
were used are included here. There is reason to 
believe that the data from Statistics Norway are 
more reliable since this body prepares figures on 
the basis of medical examiners’ post-mortem 
examination reports and death certificates in ac-
cordance with the WHO’s ICD 10 codes.
In 2007, 248 new cases of HIV infection were re-
ported. Only 13 of these cases were among injec-
ting drug users. The number of HIV-cases has 
remained relatively low for a number of years, 
and little new infection is detected in this group.
Since the turn of the millennium, only sporadic, 
individual cases of hepatitis A have been repor-
ted among drug users. On the other hand, there 
has been a considerable increase in hepatitis B 
since 1996. In 2007, 60 of a total of 118 reported 
cases of acute hepatitis B were among injecting 
drug users.
In Norway, hepatitis C is not monitored to the 
same extent as hepatitis A and B, and the num-
ber of new cases of drug users being infected is 
therefore not known. From 1 January 2008, the 
notification criteria for hepatitis C have been 
changed, so that we can expect a better overview 
of the incidence among injecting drug users next 
year.
Medically assisted treatment (MAT) can undou-
btedly be argued to be an important factor in the 
effort to prevent overdoses. The design of and 
participation in the Norwegian programme pro-
bably contribute to reducing the annual number 
of overdose deaths to a considerable extent. The 
MAT programme is big in the Norwegian con-
text, and the number of clients is steadily increa-
sing. By the end of 2007, the programme inclu-
ded more than 4,500 persons, mostly injecting 
drug users.
Oslo is the only municipality that has made use 
of the trial scheme for injection rooms. On as-
signment for the Ministry of Health and Care 
Services, the Norwegian Institute for Alcohol 
and Drug Research has evaluated the trial sche-
me in Oslo in its first two years of operation, Fe-
bruary 2005-February 2007. The report was pub-
lished in January 2008.
The state gave grants to low-threshold health 
services for substance abusers in 34 municipali-
ties in 2007. A comprehensive evaluation was 
carried out of the services in 2007. The overri-
ding goal was to answer the question of whether 
the services contribute to establishing an ade-
quate service for substance abusers, mostly hard-
core drug addicts, who do not use or are not 
reached by the ordinary health services. In the 
report, it is stated that, in general, the services 
appear to succeed in providing good help for 80 
per cent of the users, while 20 per cent do not get 
sufficient help for various reasons.
Reported drug offences
Following an increase from 2005 to 2006, the 
number of reported drug offences fell in 2007. 
The use of drugs and drug crimes pursuant to 
the General Civil Penal Code were as frequent as 
in 2006. Thirteen hundred cases of the most seri-
ous type of drug crimes were registered in 2007, 
slightly up on previous years.
The number of arrests in 2007 on suspicion of 
driving under the influence of alcohol or other 
substances shows little change in relation to pre-
vious years. The number of cases in which drugs 
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number of seizures, the proportion of methamp-
hetamine is increasing substantially in relation 
to amphetamine. It was approximately 35 per 
cent in 2007. There is no evidence to indicate 
that the importation and distribution of amphe-
tamine and methamphetamine has changed, and 
Norway is probably still a substantial market for 
these two drugs in the European context.
While both the number of seizures and the 
amount of cannabis seized declined, the cultiva-
tion of cannabis plants was uncovered on an ex-
tensive scale. During the last six months of 2007 
and into 2008, the police uncovered a large num-
ber of «plantations» in rented houses, particu-
larly in Eastern Norway. The vast majority of the 
«gardeners», and probably also the ringleaders, 
are of Vietnamese origin.
As for prices, the price level for smaller quantiti-
es in 2008 seems to have largely remained stable 
for most of the types of drugs since the last over-
view produced by the police in 2006. In nominal 
terms, prices have probably fallen slightly, rather 
than the opposite. The most striking develop-
ment is that the price of cocaine appears to have 
fallen for typical sales doses. Naturally, prices for 
drugs on the illegal street market are far from ac-
curate and thus must be treated with considera-
ble caution.
and other intoxicating medicinal drugs were 
found in blood samples has remained stable for 
the last five years, at approx. 4,000 cases.
Tetrahydrocannabinol (THC) is one of the most 
frequently found substances in blood samples 
from arrested drivers, besides alcohol. The pro-
portion of cases in which THC is found appears 
to be relatively stable, at around 30 per cent of 
the samples received. In recent years, methamp-
hetamine has been increasingly found in blood 
samples from arrested drivers, while the trend 
for amphetamine appears to be declining.
Drug markets
The most striking development in 2007 was the 
large reduction in the amount of heroin seized. 
While the number of seizures again increased 
somewhat after a steady decline during the last 
six to seven years, much less heroin was seized in 
2007 than in the preceding years, eight kilos – 
compared with 93 kilos in 2006. Even though the 
quantity seized is a less reliable indicator of prev-
alence than the number of seizures, it is none-
theless the case that so little heroin has not been 
seized since 1990. The reduction most probably 
does not reflect availability to the same extent. 
The price level has remained more or less un-
changed, and no reports have been received of a 
heroin drought of any length. In the first half of 
2008, the situation has changed in that several 
large seizures have been made and the number 
of seizures is again increasing.
Record amounts of amphetamine and methamp-
hetamine were seized in 2007. In terms of the 
PART A 
New developments and trends
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1.1 Legal framework
The temporary Act relating to injection rooms1 
(discussed in NR 2007, Chapter 1.1) applies until 
16 December 2009. On 31 October 2008, a con-
sultation proposal was distributed in which it is 
proposed to make the Act permanent. The pro-
posal means that it will be up to the individual 
municipalities to establish injection rooms as 
part of their overall services. It is proposed to 
discontinue the state grants that were available as 
part-financing during the trial period. The Regu-
lations that have been issued will largely be con-
tinued in their present form in order to enable 
the measure to be defined as a health service.
Waiting list guarantee  
for children and young people
In April 2007, the Government presented Propo-
sition No 53 to the Odelsting (2006–2007) in 
which it proposed authorising the issuing of reg-
ulations containing a statutory waiting list guar-
antee for children and young people under the 
age of 23 with mental illnesses and substance 
abuse. The proposition was adopted in Decem-
ber 2007 and the regulations entered into force 
on 1 September 2008. The waiting list guarantee 
is intended to ensure that no one who is entitled 
to necessary medical help shall have to wait for 
more than maximum 65 working days for treat-
ment, and everyone will be entitled to an evalua-
tion within 10 working days (as opposed to 30 
working days for those over the age of 23). See 
also Chapter 5.1.
On 22 April 2008, the Ministry of Health and 
Care Services distributed a proposal for consul-
tation that will make it a statutory requirement 
for health personnel to contribute to attending to 
1  Temporary Act No 64 of 2 July 2004 relating to a trial scheme 
for premises for the injection of drugs (the injection room 
scheme)
the needs of children when parents, as a result of 
mental illness, drug addiction/alcoholism, seri-
ous somatic illness or injury, are not capable of 
or are unable to provide a child with the neces-
sary help and care. The purpose of the amend-
ments to the law is to ensure that the children of 
such patients are identified and taken care in a 
better and more systematic way than at present. 
The children and parents will be given informa-
tion and guidance, and they will be consulted. 
Among other things, this will require changes in 
the duty of confidentiality to which health per-
sonnel are subject. It is also proposed that the 
specialist health service shall, insofar as necessa-
ry, have health personnel with particular respon-
sibility for following up children.
1.2  Institutional framework, 
strategies and policies
The Minister of Health and Care Services has 
overall responsibility for drugs and alcohol poli-
cy in Norway and for coordinating efforts in the 
field. Drugs and alcohol policy involves several 
different sectors and requires cooperation and 
coordination across ministry and agency bound-
aries. Moreover, there is a tradition in Norway 
for pursuing a holistic alcohol and drugs policy, 
and there will therefore be one integrated action 
plan for the whole field.
In addition to the Ministry of Health and Care 
Services, the most involved ministries are the 
Ministry of Labour and Social inclusion, the Mi-
nistry of Children and Equality, the Ministry of 
Justice and the Police, the Ministry of Local Go-
vernment and Regional Development and the 
Ministry of Education and Research. The respec-
tive directorates, the Norwegian Institute for Al-
cohol and Drug Research, AS Vinmonopolet, the 
county governors and the regional drugs and al-
cohol competence centres all have important re-
sponsibilities in the field of drugs and alcohol 
1. National policies and context
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overview of the progress and status of each indi-
vidual measure and for the plan as a whole. In 
other respects, the general division of responsi-
bility in the public administration will apply.
The Directorate of Health (formerly the Directo-
rate for Health and Social Affairs) is an executive 
and advisory body in the drugs and alcohol field. 
It is responsible for implementing large areas of 
the drugs and alcohol policy. The Directorate has 
wide-ranging responsibility for the escalation 
plan and it has chief responsibility for 58 of the 
147 individual measures in the plan. Moreover, it 
shall ensure that an overview of the drugs and 
alcohol situation is available at the regional and 
local level, and it will publish an annual status re-
port.
Responsibility for interdisciplinary specialist tre-
atment has been assigned to the four regional 
health authorities. Norwegian drugs and alcohol 
policy is decentralised to a great extent, and the 
municipalities have been delegated considerable 
responsibility for prevention, rehabilitation and 
reintegration of substance abusers in the local 
community.
Evaluation of policies and strategies
Many of the measures in the escalation plan will 
be specified in more detail during the plan peri-
od. In order to ensure systematic further devel-
opment and implementation, a system of coordi-
nation meetings between affected ministries and 
relevant subordinate agencies has been estab-
lished. The Ministry of Health and Care Services 
will be in charge of coordination, and it will also 
be responsible for coordinating the escalation 
plan with other plans. The status and progress of 
the different measures will be reported annually 
to the Ministry of Health and Care Services, and 
this reporting will form the basis for an annual 
summary of the attainment of goals and the 
progress of the measures.
In connection with the Directorate of Health’s 
grant schemes, great emphasis is placed on eva-
luating the measures and earmarking funds for 
such evaluations. The goal is to contribute to im-
policy. Good contact and cooperation between 
the different bodies is emphasised.
1.2.1  Norwegian National Action Plan on 
Alcohol and Drugs
In October 2007, as part of Proposition No 1 to 
the Storting (2007–2008) for the Ministry of 
Health and Care Services, the Government pre-
sented an escalation(action) plan for the drugs 
and alcohol field. It includes goals and measures 
for prevention, treatment and rehabilitation and 
entails a gradual escalation of funding in this 
field in the period up until 2010.
The plan includes alcohol and drugs policy as 
well as national and international measures. The 
plan aims for a policy with a clear public health 
perspective. The aim is to raise professional stan-
dards through research and by strengthening 
competence and quality. As regards services, the 
principle is that the ordinary services should also 
be available to people with drug or alcohol pro-
blems. Cooperation between the different bodies 
and administrative levels is emphasised, as is the 
user perspective. The overriding goals are:
•	 A	clear	public	health	perspective
•	 Better	quality	and	increased	competence
•	 More	accessible	services	and	greater	social	
inclusion
•	 Binding	cooperation
•	 Increased	user	influence	and	greater	
attention to the interests of children and 
family members
See NR 2007 Chapter 1 for a more thorough de-
scription of the performance goals in the escala-
tion plan.
Implementation of policies and strategies
The involved ministries shall cooperate during 
the plan period on continuous follow-up of the 
National Action Plan for Alcohol and Drugs. The 
plan assigns chief responsibility for each measure 
to a specific body. That body will be responsible 
for instigating measures and involving affected 
parties. Separate reporting procedures have been 
developed for the escalation plan that provide an 
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In 2007, the cost of interdisciplinary specialist 
treatment for problem drug and alcohol users 
amounted to EUR 287.5 million2 (NOK 2.3 bil-
lion) of the regional health authorities’ budgets. 
The figure includes the treatment of both alcoho-
lics and drug addicts. However, the estimate only 
includes institutions specifically aimed at drug 
addicts and alcoholics. The costs of treatment of 
drug and alcohol problems at other institutions 
(for example in the mental health care services) 
cannot be quantified, and it will therefore come 
in addition.
In the national budget for 2008, an additional 
EUR 15.63 million (NOK 125 million) was allo-
cated to the drugs and alcohol field for following 
up and implementing measures in the escalation 
plan. The allocations break down as follows:
•	 EUR	5.75	million	(NOK	46	million)	to	boost	
acute treatment, detoxification and MAT
•	 EUR	1.5	million	(NOK	12	million)	for	the	
establishment of a system of drugs and 
alcohol advisers at the county governor 
offices
•	 EUR	2.88	million	(NOK	23	million)	for	trial	
schemes with «special coordinators» in the 
municipalities
•	 EUR	0.88	million	(NOK	7	million)	for	
prevention and early intervention
•	 EUR	0.88	million	(NOK	7	million)	for	dental	
health services for persons in MAT
•	 EUR	0.38	million	(NOK	3	million)	to	boost	
drugs and alcohol research
•	 EUR	0.25	million	(NOK	2	million)	to	
strengthen the regional drugs and alcohol 
competence centres
•	 EUR	2.13	million	(NOK	17	million)	for	
municipal measures in the drugs and alcohol 
field
•	 EUR	1	million	(NOK	8	million)	for	the	
Pathfinder prison project
2  Conversion rate 1 EUR=NOK 8.00
proving quality and supporting knowledge-bas-
ed strategies and measures by ensuring continui-
ty and local support.
1.2.2 New research centre
The Norwegian Centre for Addiction Research - 
SERAF, which was established in autumn 2007, 
is located in the same premises as the Medica-
tion Assisted Rehabilitation centre for South-
eastern Norway and the department of specialist 
outpatient clinics in the Clinic for Drug Abuse 
and Dependence at Aker University Hospital.
The Centre (www.seraf.uio.no/eng) will prima-
rily focus on clinically relevant drug research. 
The Centre shall have a national role in recruit-
ment and education, functioning as a network 
builder for drug research in Norway.
SERAF shall have an intra-faculty function and 
multidisciplinary composition, and it shall re-
present sound expertise at international level in 
clinically relevant drug research. The research 
will be organised in four research groups:
1 Vulnerability to and development of 
dependency conditions
2 Drug-related and co-morbid conditions
3 Interventions – treatment and prevention
4 Health service research.
The research centre will be evaluated after five 
years and, provided that the evaluation is posi-
tive, it will be maintained for a further five 
years.
1.3  Budget and public expenditure
Law enforcement
No comprehensive overview is available.
Social and health care
Alcohol and drug-related tasks are part of the or-
dinary services. Isolating and quantifying costs 
from the social and care services that relate to 
drug problems is very complicated, and such fig-
ures can therefore often be misleading.
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challenges, and measures that promote integra-
tion are given high priority. These measures will 
specifically target young people who make little 
use of existing cultural and leisure services and 
provide better opportunities for qualification, in-
clusion and coping.
Grants for Voluntary work etc. are administered 
by the Directorate of Health. The grants are gi-
ven in the form of project and operating grants 
for voluntary organisations in the drug and alco-
hol prevention field. The purpose is to help orga-
nisations that work to reduce the consumption 
and harm caused by drugs and alcohol to carry 
on and develop their efforts. The allocation for 
2008: EUR 11.3 million (NOK 90.4 million).
Research
State funding is allocated annually to the Norwe-
gian Institute for Drug and Alcohol Research-
SIRUS and other research milieus (Table 1).  
Table 1: Grants for research and dissemination in 
2008. In EUR (NOK) million.
SIRUS 4.373 (34.982)
The Behavioural Centre 0.375 (3)
National Institute of Public Health* 1.250 (10)
The research programme – Research 
Council of Norway/SERAF 
2.312 (18.5)
Drugs and alcohol research conducted 
by the regional health authorities**
1.875 (15)
Total* 9.810 (81.482)
*Approximate figure
** Approximate figure for 2007
Regional drugs and  
alcohol competence centres
Annual grants are paid to the seven regional 
drugs and alcohol competence centres in Nor-
way. Allocation for 2008: EUR 8.25 million 
(NOK 66 million).
The competence centres are an important link 
between the state and municipalities and regio-
nal health authorities in connection with the dis-
semination and implementation of research-bas-
The strengthening of the municipal sector and 
the specialist health service comes in addition. 
In the national budget proposal for 2009, it is 
proposed to increase the allocation to the drugs 
and alcohol field by EUR 37.5 million (NOK 300 
million).
Special grant schemes
In addition to the ordinary block grant funding 
allocated to municipalities and health authori-
ties, funds are channelled to special-priority pur-
poses through grant schemes that are largely ad-
ministered by the Directorate for Health. The 
grant schemes are divided between two items in 
the national budget:
Grants for municipal drug and alcohol measu-
res - 2008: EUR 21.59 million (NOK 172.7 mil-
lion). Among other things, grants shall be used 
to strengthen personal guidance and individual 
follow-up, low-threshold health measures for al-
coholics and drug addicts, a trial scheme for in-
jection rooms, dental health services for people 
with drug or alcohol problems and publications 
such as «=Oslo».
Voluntary drug and alcohol prevention work etc. 
– 2008: EUR 14.98 million (NOK 119.8 million). 
Grants are earmarked for follow-up, care and re-
habilitation services run by voluntary organisa-
tions and private undertakings, self-help and in-
terest groups and work among family members, 
measures aimed at prostitutes and The street 
hospital in Oslo. In addition, EUR 444,425 (NOK 
3.55 million) is channelled through the regional 
drug and alcohol competence centres in order to 
stimulate efforts by the municipalities and spe-
cialist health service.
The grant scheme Measures among children and 
young people in large towns and cities is admi-
nistered by the Ministry of Children and Equali-
ty. Grants for youth measures are given to 23 ur-
ban municipalities and, in 2008, they amount to 
EUR 2.1 million (NOK 16.8 million). These me-
asures should target youth groups and youth mi-
lieus that are deemed to be at risk. Young people 
from immigrant backgrounds face particular 
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1.4 Social and cultural context
Mass media campaigns
In order to increase awareness about the damage 
alcohol can result in and to increase knowledge 
about which methods work best, the Directorate 
of Health also ran the campaign – www.setteg-
renser.no in 2008. Such campaigns are followed 
up at the local level, among other things through 
cooperation with the parents council for primary 
and lower secondary schools. Young people and 
parents are particularly important target groups 
and there must be agreement between the infor-
mation aimed at these two groups. In addition, 
people from immigrant backgrounds and preg-
nant women are given priority. More emphasis 
will be placed on adapting information to suit 
the section of the population at which it is aimed. 
Moreover, the Directorate’s information efforts 
should support and strengthen the understand-
ing that a restrictive alcohol policy is necessary.
ed knowledge and recognised methods. They 
have three main purposes:
•	 to	stimulate	the	development	of	preventive	
measures in the municipalities
•	 competence-building	in	the	municipalities	
and the specialist health service
•	 to	develop	national	areas	of	expertise
The most important users of the centres’ services 
are employees in municipal services and the spe-
cialist health service.
International actions
Grant for 2007 to UNODC: EUR 3 million (NOK 
24 million).
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The percentage of 15–20 year-olds in Norway 
who state that they have ever used hash or mari-
juana has been around 11 to 13 per cent during 
the last few years, while the proportion reporting 
having used the drug during the last six months 
has been around six per cent. The corresponding 
percentages around the turn of the millennium 
were approximately 18 and 9–10 per cent, re-
spectively. If we look at the same age group 
among those who live in Oslo, there has also 
been a steady reduction in the proportion who 
report ever having used cannabis. In the last few 
years, slightly less than 20 per cent report having 
used cannabis, while around nine per cent report 
having used cannabis during the last six months. 
The corresponding percentages around the turn 
of the millennium were approximately 28 and 16 
per cent, respectively (Figure 2).
Figure 2: The percentage of youth between the ages 
of 15 and 20 in Oslo who state that they have taken 
cannabis: ever and during the last six months, re-
spectively, 1968 – 2007 (three-year sliding average).
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The proportion who state that they have used 
other drugs also increased in the late 1990s be-
fore largely stagnating/ declining in recent years 
(Figures 3 and 4). For example, the proportion of 
15–20 year-olds in the country as a whole who 
state that they have ever used amphetamine has 
been around three to four per cent in the last two 
to three years, while the proportion stating that 
they have ever used ecstasy has remained at 
2.1  Drug use in the general  
population
No new information available. The most recent 
survey of the general population’s drug use was car-
ried out by SIRUS in autumn 2004. The main re-
sults were discussed in NR 2005, chapter 2.1. The 
next nationwide survey is scheduled for 2009.
2.2  Drug use in the school and 
youth population
2.2.1 Drug use among youth aged 15–20
Data have been analysed from the annual ques-
tionnaire survey among young people aged be-
tween 15 and 20 in 2007. Since the division into 
age groups and questions about recent drug use in 
this survey are not in harmony with the division 
used by the EMCDDA, the data cannot be includ-
ed in standard tables.
Cannabis, primarily in the form of hash, is the 
drug most young people report having used. After 
peaking at the turn of the millennium, a reduction 
has been registered in recent years (Figure 1).
Figure 1: The percentage of youth between the ages 
of 15 and 20 in Norway who state that they have 
taken cannabis: ever and during the last six months, 
respectively, 1986 - 2007.
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2. Drug use in the population
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measured by questions about whether young 
people had been offered various drugs, or belie-
ved they could obtain them. The proportion of 
15 to 20 year-olds in the country as a whole who 
state that they have ever been offered cannabis 
has been around 30 to 40 per cent for the last five 
years, while the proportion who believe that they 
could obtain cannabis in two to three days if they 
so wished has been around 50 to 65 per cent. In 
around two to three per cent for several years. 
The corresponding figures for Oslo are two to 
four per cent for amphetamine and the same for 
ecstasy. The decline appears to be somewhat gre-
ater among young people in Oslo than in the co-
untry as a whole.
There does not seem to have been any increase in 
the availability of illegal drugs in recent years as 
Figure 4: Percentage of youth between the ages of 15 and 20 in Oslo who have ever used various drugs,1970 – 
2007 (three-year sliding average).
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Figure 3: Percentage of youth between the ages of 15 and 20 in Norway who have ever used various 
drugs,1986 – 2006.
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falling response rate, there is further reason to 
emphasise that there is uncertainty attached to 
the results from one single year. The purpose of 
the surveys is primarily to serve as a tool for exa-
mining trends over time. Given that the youth 
surveys have been carried out for so many years, 
they represent time series that are relatively uni-
que in the international context, and they are 
therefore assumed to be useful even though the 
response rate has been relatively low in recent 
years.
2.2.2 Hash use among young adults
Data from SIRUS’s questionnaire surveys among 
young adults aged between 21 and 30 were pre-
sented in NR 2007 Chapter 2.2.2.
A study
A representative sample of young women and 
men have, since they were in their teens in 1992 
until they became adults in 2005, answered a 
questionnaire about cannabis on four occasions 
(Pedersen, 2008). They were also asked about 
their parents’ education and social class, about 
their own education and position in the employ-
ment market, about whether they have received 
social security or welfare benefits, and about 
their income. In addition, various measures of 
marital status/partnership and starting a family 
were examined. The study is based on Young in 
Norway – a longitudinal study, which is de-
scribed in detail by Strand and von Soest (NOVA 
2006). A sample of 2,819 persons answered the 
questionnaire on all four occasions, which means 
an accumulative response rate of more than 70 
per cent for all the surveys.
Results
At the age of 15 to 16, less than ten per cent had 
experience of using cannabis, but quite a few made 
their debut with the drug in their late teens and 
also during their twenties. At the end of their 
twenties, 40 per cent of the men and 29 per cent of 
the women had used cannabis at some time, and 
18 per cent of the men and eight per cent of the 
women has used cannabis during the past year 
(both differences between the sexes p < 0.001).
the country as a whole, the proportion who state 
that they have been offered amphetamine, co-
caine and ecstasy has been around 7 to 13 per 
cent in the last two to three years.
If we look at 15 to 20 year-olds in Oslo alone, the 
proportion who state that they have been offered 
cannabis is around 40 to 50 per cent, while slight-
ly more than 60 per cent believe they could ob-
tain cannabis in the space of two to three days. In 
Oslo, the proportion who state that they have 
been offered amphetamine, cocaine or ecstasy 
has been around 10 to 15 per cent in the last two 
to three years.
Otherwise, the 2007 survey confirms the trend 
we have seen in recent years that the proportion 
expressing a positive attitude to drugs is no lon-
ger increasing. During the last two to three years, 
approximately six to eight per cent of 15 to 20 
year-olds in the country as a whole and seven to 
ten per cent in Oslo have expressed the opinion 
that it should be permitted to sell cannabis freely 
here in Norway.
Statistical margins of error
Note that the figures are subject to statistical 
margins of error and must be interpreted with 
great care. Moreover, it is important to bear in 
mind that questionnaire surveys are always sus-
ceptible to certain sources of error (not everyone 
responds, some responses may contain deliber-
ate or inadvertent errors etc.), and that the sur-
veys referred to here target young people in gen-
eral. There is reason to believe that young people 
who regularly use drugs, either cannabis or 
stronger substances, will be underrepresented in 
the surveys.
In the annual youth surveys up until the mid-
1990s, approximately 70 per cent answered the 
questionnaire, but the response rate has fallen to 
between 40 and 50 per cent in recent years. This 
is worrying, and it is probably related to the fact 
that very many questionnaire surveys have been 
carried out among young people in recent years. 
It is not unlikely, therefore, that a certain ‘fatigue’ 
arises among respondents. On the basis of the 
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high probability of dropping out of the study 
(Pedersen, 2008).
The study complements the picture provided by 
other studies carried out in recent years. This ap-
plies in particular to Drug use among young 
adults aged 21 to 30 (discussed in NR 2007, 
Chapter 2.2.2) in connection with which SIRUS 
have collected data. In this study, the proportion 
who have ever used cannabis in Norway increa-
sed from 22 per cent in 1998 to 34 per cent in 
2006, while the proportion reporting recent use 
(here: The last six months) did not increase from 
2002 to 2006 (Table 2). The 21 to 25 age group 
was highest here, with 12 per cent both years, 
while approximately nine per cent in the 26 to 30 
age group reported use during the last six 
months. The incidence among men is more than 
double that among women. A low and falling re-
sponse rate is a problem in connection with this 
study as well, and this can be assumed to result 
in underestimation of use.
Table 2: The percentage between the ages of 21 and 
30 in Norway who state that they have used canna-
bis during the past six months. By age group, 
gender and survey year.
Year Age
NORWAY
Women Men All
1998
21–25 5 12 9
26–30 4 9 6
2002
21–25 7 17 12
26–30 5 11 8
2006
21–25 8 15 12
26–30 4 13 9
Source: SIRUS
2.3  Drug use among specific 
groups
2.3.1.  Drug use among persons from 
immigrant backgrounds
Quantitative research carried out on large popu-
lations shows that immigrant youth as a group 
use drugs less than Norwegian youth. Qualita-
tive surveys also indicate that the use of alcohol 
and drugs is smaller and more controlled than 
In the teenage years, there were no significant 
differences between the sexes as regards the use 
of cannabis. Use in the teenage years was not as-
sociated with social marginality and low social 
class among parents, but, during their twenties, 
the cannabis users were increasingly young, sin-
gle men with interrupted education who were 
outside the employment market.
Many respondents, particularly among the young 
men, make their debut with cannabis in their 
twenties. It is surprising that as many as 30 per 
cent of young men in their late twenties who live 
in Oslo have used cannabis during the past year. 
In the group with low education and among tho-
se who are outside the employment market, the 
proportion who use drugs is much higher than 
this. However, it must be pointed out that most 
respondents in the sample report low-frequent 
use of cannabis.
Moreover, the study shows that the recruitment 
base during the respondents’ early teens is not 
characterised by low social class or social margi-
nality among the parents. On the other hand, 
however, a pattern develops with increasing age 
whereby young adults who have dropped out of 
school and who have failed to find a foothold in 
the employment market are more likely to beco-
me cannabis users. Those who do not marry or 
form partnerships during their twenties are also 
at increased risk. A single man, resident in the 
Oslo region, with an interrupted education and 
not in permanent employment who lives off so-
cial security or welfare benefits will have a high 
probability of being a cannabis user.
The study is assumed to be representative and 
has a good response rate. It forms a good basis 
for studying the prevalence of cannabis use 
among the young adult population in Norway. 
However, there is an accumulated dropout rate 
of 30 per cent for the four data collections. Previ-
ous analyses show that dropping out is selective 
in a manner that means that there are probably 
more cannabis users among the dropouts than in 
the sample as a whole. It must be assumed, not 
least, that regular use of cannabis entails a very 
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About hash in particular
Five of the surveys contained questions about 
the use of hash.
Adults 2004: SIRUS’s nationwide survey of drug 
and alcohol use among adults in 2004 included 
3,191 persons in the age group 15 and above (see 
NR 2005 Chapter 2.1 for more information).
Young adults 2006: SIRUS’s survey of drug and al-
cohol use among persons aged between 21 and 30 
from 2006 included a total of 4,193 persons (see 
NR 2007 Chapter 2.2.2 for more information).
Attitudes (HoldRus): The survey was carried out 
by SIRUS and the Alcohol and Drug Addiction 
Service to study drug and alcohol use and attitu-
des to the use of drugs and alcohol among stu-
dents at lower secondary schools in Oslo. The 
survey’s gross sample included students at six 
schools in the Oslo area who completed the se-
venth, eight and ninth forms in 2002. The survey 
was repeated among the same students in the 
four following years. A total of 4,396 question-
naires were completed, and the response rate va-
ried between 86 and 90 per cent.
Youth 2006/2007: SIRUS’s annual survey on the 
use of drugs and alcohol among young people 
covers the 15 to 20 age group. See Chapter 2.2.1. 
Questions about immigrant background were 
included from 2006. In order to strengthen the 
sample, the figures from the 2006 and 2007 sur-
veys are shown combined. The total number of 
respondents for the two years was 8,108.
The Schools Survey 2004: SIRUS’s survey of 
drug and alcohol use and its consequences in 
connection with the evaluation of the Regional 
Project – see Chapter 3 for more information. 
The gross sample in the survey consisted of all 
students in lower and upper secondary schools 
in 16 selected municipalities outside the big 
towns and cities in Norway. The gross sample for 
2004 consisted of 25,872 students from 91 
schools. A total of 20,703 forms were completed. 
The response rate was 80 per cent.
among youth from Norwegian backgrounds. At 
the same time, however, since the turn of the 
millennium, an open drugs and alcohol scene 
that is dominated to a great extent by teenage 
boys and young men from immigrant back-
grounds has emerged along the Akerselva river 
in Oslo city centre. In addition, there are signs 
that there has been an increase in the numbers of 
immigrant youth in the hardest drug milieus in 
Oslo, and that the use of drugs and alcohol and 
problem use is greater among immigrants and 
immigrant youth than previously assumed 
(Bergengen and Larsen, 2008).
Quantitative surveys
Since 2004/2005, SIRUS has asked respondents 
about their own and their parents’ birthplace in 
its questionnaire surveys. This provides an op-
portunity to report on drug and alcohol use 
among groups of persons from immigrant back-
grounds (Vedøy and Amundsen, 2008).
Data from seven surveys has been used to de-
scribe the use of alcohol, cigarettes, oral moist 
snuff and cannabis among young people and 
adults with backgrounds from different countri-
es, in both Oslo and Norway as a whole. Based 
on Statistics Norway’s definition of immigrants, 
figures have been presented for the different con-
tinents. This is because categorisation by country 
of birth would result in many categories often 
containing a small number of cases. For the sur-
veys carried out among adults, the continent was 
decided by the respondents’ country of birth. 
Among young people, the continent was decided 
on the basis of the father’s place of birth.
Statistics Norway defined the immigrant popula-
tion as «persons with two parents born abroad: 
first-generation immigrants who have migrated 
to Norway, and persons born in Norway with 
two parents who were born abroad». Respon-
dents’ own country of birth is defined as the 
mother’s country of residence when the respon-
dent was born.
The Drug Situation in Norway 200820
fathers born in Asia or Africa were more restric-
tive with respect to the use of hash. The category 
that uses hash most is boys from Norway and 
Europe. We also find that youth in Oslo are less 
restrictive in terms of using hash than youth in 
the rest of the country.
The use of hash varies to a certain extent with 
national background, and it is among people 
from Norwegian and European backgrounds 
that we find the largest proportion who state that 
they have tried hash. However, it appears that the 
differences between the surveys, i.e. between the 
different age groups, are greater than the diffe-
rences between persons from different national 
backgrounds.
Among ethnic Norwegians, the figure for ever 
having used hash is clearly higher among young 
adults than among adults as a whole. The same 
cannot be claimed to apply to persons from im-
migrant backgrounds from Asia and Africa, 
partly because the differences are less than for 
ethnic Norwegians and partly because the num-
ber of respondents is too low. So, again with all 
the necessary reservations, immigrants from 
Asian backgrounds do not seem to be picking up 
Norwegian (bad) habits as regards the use of 
hash. The higher risk of non-Western immi-
grants being offenders in drug crimes is not re-
flected in hash use as measured in population 
surveys.
Few of the surveys in this report enable more 
thorough analyses to be carried out of how drug 
and alcohol use varies with, for example, socio-
economic status, degree of assimilation or inte-
gration etc. There are also few of the surveys that 
include so many persons that it is possible and 
meaningful to carry out quantitative analyses of 
specific drug/alcohol cultures.
Statistical sources of error
In population surveys, there are some margina-
lised groups that do not take part. Heavy drug 
and alcohol use among persons of no fixed abode 
or who move frequently, for example in and out 
of treatment, will therefore not be reported. In 
Among adults from  
immigrant backgrounds
The survey shows that it was more common to 
have smoked hash among adults from immigrant 
backgrounds born in Norway or Europe than 
among persons from immigrant backgrounds 
from Asia and Africa. In all the surveys, we also 
found that a larger proportion of persons born in 
Europe had tried hash than of persons born in 
Norway (Figure 5). We also found that the pro-
portion was higher among young adults than in 
the Norwegian population as a whole. In addi-
tion, the use of hash among young adults was 
more common in Oslo than in the rest of the 
country.
Figure 5: Percentage of adults who have ever 
smoked hash grouped by place of birth.
16
26
11
16
48
58
21
25
 43 46
34
40
15
 33 34
0
10
20
30
40
50
60
70
Norway Europe Asia Africa America Total
Adults 2004 Young adults 2006 OSLO Young adults 2006 NORWAY
Source: SIRUS
Among youth
On the basis of the four surveys, we find that the 
use of hash among lower secondary school stu-
dents varies somewhat with national back-
ground, but there is great variation between the 
surveys and the results point in several different 
directions. The main tendency is that the use of 
hash is greater among youth in Oslo than in the 
rest of the country and that young people with 
fathers from Europe are least abstentious in rela-
tion to hash use.
If we look at the surveys together and examine 
the use of hash by father’s country of birth, the 
main tendency was that young people with 
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As part of the overview of current knowledge, 
experience-based material was also collected 
from 34 selected municipalities (of 53 asked) and 
14 wards in Oslo. In terms of the information re-
ported by the individual municipalities, there 
appear to primarily be differences between town 
and country. Naturally, Oslo clearly stands out, 
because it is the biggest city and has the largest 
proportion of immigrants3. The main impression 
is that, except for Oslo and some of the big towns 
and cities, immigrant youth and drug and alco-
hol use is not much of an issue. The figures for 
the other municipalities are so small that it is a 
matter of individuals rather than groups.
Immigrant youth as a group use drugs and alco-
hol less and their use is more controlled than 
among Norwegian youth, although there has 
been an increase in the number of immigrant 
youth in the hardest drug milieus in Oslo. The 
differences between boys and girls’ use of alcohol 
are small among youth from Norwegian back-
grounds. Among immigrant youth, there is a 
clear preponderance of boys among those who 
have drunk alcohol. The differences between 
youth from Norwegian backgrounds and youth 
from immigrant backgrounds are smaller in re-
lation to the use of other drugs than alcohol.
3  As of 1 January 2006, 36 per cent of the non-Western im-
migrant population lived in Oslo. If the neighbouring county 
of Akershus is included, 46 per cent live in what is normally 
referred to as the Oslo area www.ssb.no.
school surveys among young people, those who 
are frequently absent without reason because of 
antisocial tendencies and who probably have 
higher drug and alcohol use will not take part. 
Moreover, most people will have a tendency to 
be somewhat biased in their reporting in the di-
rection of the norms for and social desirability of 
drug and alcohol use within their own culture/
social group. Ethnic Norwegian youth may well 
over-report drug and alcohol use, while ethnic 
Norwegian adults and Muslims regardless of age 
may well under-report such use (Vedøy and 
Amundsen, 2008).
Other surveys
The Oslo Drug and Alcohol Addiction Service 
Competence Centre has produced an overview 
of what is known about drug and alcohol use 
among immigrant youth (Bergengen and Larsen, 
2008). In the summary of various self-report 
surveys, several of which have already been men-
tioned, it is confirmed that a large proportion of 
immigrant youth report less drug and alcohol 
use than ethnic Norwegian youth, but there are 
exceptions.
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ties and a questionnaire survey at all the lower 
secondary schools in Oslo and among parents.
The study shows that most schools, roughly 75 
per cent, implement the programme in full. The 
reason why some schools did not implement all 
the components has to do with the high propor-
tion of foreign language speakers among stu-
dents or that the schools were already involved 
in other preventive programmes in the field. The 
results of the evaluation showed that the follo-
wing factors are important in connection with 
implementation:
•	 Support	must	be	ensured	for	the	programme.	
In Oslo this was done through a decision of 
the City Council stating that an alcohol 
prevention programme was mandatory.
•	 Raising	competence	is	decisive.	In	Youth	&	
Alcohol, this means providing courses for 
teachers and group leaders. The Educational 
Service and Oslo Drug and Alcohol 
Addiction Service Competence Centre 
followed up the decision by organising a 
seminar for teachers and helping to finance 
the training of group leaders.
•	 The	schools’	management	must	follow	up	the	
decision to implement the programme. In 
Oslo, this meant that those in charge of 
schools had to ensure that information about 
Youth & Alcohol was mandatory and was 
received by all teachers. The decision also 
had to be followed up by sending teachers on 
courses.
•	 Structural	factors	at	individual	schools	are	
important. In Oslo, factors such as sufficient 
time, technical equipment, finances, 
planning work and the proportion of 
students from multicultural backgrounds 
proved to be important.
•	 Individual	participants’	motivation	and	
competence in relation to the different parts 
of the programme. The analyses show that 
The Government’s escalation plan for the drugs 
and alcohol field in Norway (discussed in Chap-
ter 1) includes efforts to raise professional stan-
dards in preventive work in Norway. Informa-
tion work will be strengthened, with more 
targeted information and more participation by 
young people and parents. Knowledge must be 
built and attitudes changed in order to reduce 
the harmful effects. Public support for the volun-
tary sector will continue as part of the quality 
boost, preventive measures will be coordinated 
and the work on drug and alcohol prevention in 
the workplace will be intensified (the Ministry of 
Health and Care Services, 2008).
3.1 Universal prevention
The Youth & Alcohol project  
– a process evaluation
The preventive measure Youth & Alcohol (dis-
cussed in NR 2006 Chapter 3) is based on a so-
cial cognitive strategy that focuses on children 
and young people’s attitudes and norms in rela-
tion to alcohol. Central teaching methods in-
clude problem-based learning and the use of in-
formation and communications technology. The 
target group consists of eighth form students, 
teachers and parents/guardians, with follow-up 
in the ninth form. The programme has been pro-
cess evaluated with the focus on initiation and 
implementation of the programme in lower sec-
ondary schools in Oslo in the 2006/2007 school 
year. The purpose was to identify factors that in-
fluence initiation and implementation in schools, 
and to further develop and improve the web so-
lution and implementation strategies.
The evaluation methods consisted of observation 
of implementation, group interviews with selec-
ted students and teachers at selected schools, do-
cument analysis, conversations with various par-
3. Prevention
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ween municipalities. As regards adaptation and 
further development of preventive measures, lo-
cal expertise has also increased. The organisation 
of the project in the municipalities has been 
functional, and the project has had good politi-
cal and administrative support locally.
The report points out that none of the municipa-
lities in the Regional Project has implemented 
the most effective strategies in drug and alcohol 
prevention, such as restricting the availability of 
alcohol and stricter enforcement of the regula-
tions for the sale and serving of alcohol.
3.2 Selective prevention
Measures aimed at immigrant youth’s  
use of drugs and alcohol
In 2006, the then Directorate for Health and So-
cial Affairs gave the Oslo Drug and Alcohol Ad-
diction Service Competence Centre the task of 
mapping available knowledge about immigrant 
youth and their use and problem use of drugs 
and alcohol.
The intention was to examine whether and to 
what extent youth from immigrant backgrounds 
need special measures to prevent the develop-
ment of drug and alcohol problems, and whether 
or not various immigrant youth groups need se-
parate early intervention measures in the drugs 
and alcohol field. See also Chapter 2.3.1, Other 
surveys. A report was published in 2008 (Ber-
gengen and Larsen, 2008). The report contained 
the following proposals:
•	 Measures	aimed	at	youth	from	immigrant	
backgrounds should be based on
•	 existing	measures.
•	 There	should	be	greater	focus	on	violence-
related problems and problem behaviour that 
can conceal problem drug and alcohol use.
•	 There	should	be	greater	awareness	of	
problems relating to the migration 
experience.
•	 Greater	focus	should	be	placed	on	the	
resources that exist in immigrant milieus 
the schools’ management, teachers, parents/
guardians and students are generally positive 
to the programme. The evaluation also 
revealed that schools with a high proportion 
of students from multicultural backgrounds 
face special challenges relating to linguistic 
and cultural barriers in relation to alcohol as 
a topic (Steinkjer, 2008).
Evaluation of the Regional Project
In order to encourage coordination and coopera-
tion in the municipalities, the Regional Project 
was started in nine pilot municipalities in 2004 
(discussed in NR 2005, Chapter 3.3). The main 
goal was to develop effective preventive measures 
and to further develop existing measures with a 
view to limiting the use of drugs and alcohol and 
harm caused by drugs and alcohol, with the main 
focus on children and young people.
The project was evaluated by SIRUS in 2007 
(Baklien, Pape, Rossow and Storvoll, 2007). The 
analyses are based on extensive data, including 
data from interviews with players at the central 
and local levels, observations of meetings and 
the implementation of measures, questionnaire 
surveys of 40,000 school students and attempts 
to buy alcohol in shops that sell beer.
According to the evaluation report, the Regional 
Project’s main goal of reducing the use of drugs 
and alcohol and limiting drug and alcohol-rela-
ted harm among young people was not achieved 
during the period covered by the evaluation 
(2004–2006). Nor did the project contribute to 
limiting young people’s access to alcohol. The re-
port points to several possible explanations for 
the lack of results. Only a few of the measures the 
directorate recommended to the municipalities 
had a documented effect on drug and alcohol 
use and drug and alcohol-related harm. Many of 
the measures had a long time perspective, and 
some of them were implemented in incomplete 
«light» versions.
On the other hand, the project has resulted in 
some municipalities setting up new multidis-
ciplinary collaborations, both internally and bet-
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sible children growing up in families with prob-
lem drug or alcohol use, and to give them ade-
quate follow-up and help as early as possible. As 
part of the project, approximately 160 teachers 
and nursery school staff from four municipali-
ties in two counties (Telemark and Vestfold) have 
taken courses. The project has been evaluated by 
SIRUS (Baklien and Wejden,2008).
The intention of the project was to create change, 
both at the individual level and the collective le-
vel. The evaluation attempts to track these chan-
ge processes. The most important source of data 
consisted of extensive qualitative interviews with 
a total of 60 course participants and other key 
persons. The evaluation is also based on a questi-
onnaire survey and document analysis.
The proportion who state that they have sufficient 
competence to identify signs that a child is suffe-
ring because of problem drug or alcohol use in the 
family has increased considerably during the pro-
ject period. The course has created enthusiasm and 
a moral obligation in relation children who need 
help. The participants state that they have become 
more secure and more observant. There are still 
many who are reluctant to conduct the necessary 
conversation with the parents, but the informants 
find that the course has provided them with met-
hods that to a certain extent make it easier to talk to 
the parents. In other words, there is reason to be-
lieve that at least some children will receive spee-
dier and better help as a result of the project.
The project also had ambitions of creating structu-
ral and relational changes. The goal was to develop 
a model that could coordinate efforts between tho-
se who meet children who are subjected to problem 
drug or alcohol use in the family and those who 
meet parents who have drug or alcohol problems. 
This goal was not achieved. One important reason 
appears to be that it was unclear whose responsibi-
lity it was to initiate this coordination. The project 
did not take sufficient account of the preconditions 
and framework conditions that must be met if one 
is to succeed in developing new models for coope-
ration. Efforts primarily targeted changes at the in-
dividual level.
that can protect against the development of 
destructive drug and alcohol use.
•	 There	should	be	greater	focus	on	poverty-
related problems in relation to dealing.
•	 We	need	more	knowledge	about	the	use	of	
drugs and alcohol among youth from 
immigrant backgrounds, about immigrant 
girls’ use of drugs and alcohol, marginalised 
groups of youth from immigrant 
backgrounds, students and older youth from 
minority backgrounds and youth with one 
foreign and one Norwegian parent.
3.3 Indicated prevention
3.3.1 Early intervention
On assignment for the Ministry of Health and 
Care Services, the former Directorate for Health 
and Social Affairs drew up a proposal for a na-
tional strategy. The proposals were presented in 
the report ‘Early intervention in the drugs and 
alcohol field. Central perspectives - relevant tar-
get groups and arenas’, which was published in 
June 2007 (discussed in NR 2007, Chapter 3).
In 2007, 12 different intervention projects were 
initiated under the auspices of the regional com-
petence centres and financed by the Directorate 
for Health and Social Affairs. Most of them were 
projects that will run over several years and will 
receive further funding aimed at the designated 
target groups and arenas. One of the interven-
tions, ‘Children in families with drug or alcohol 
problems – early intervention’, has been evalua-
ted by SIRUS. See below.
Evaluation of the project ‘Children in 
families with drug or alcohol problems – 
early intervention’.
The project Children in families with drug or al-
cohol	problems	–	early	 intervention was devel-
oped and implemented by the Borgestad clinic’s 
competence centre in 2006 and 2007. The goal 
was to increase the action competence of staff in 
schools, nursery schools, the social services and 
the child welfare services. The intention was to 
enable those involved to identify as early as pos-
Annual report to the European Monitoring Centre for Drugs and Drug Addiction – EMCDDA 25
•	 the	Mortality	Multiplier
•	 questionnaire	surveys	among	the	police	and	
the social services in the municipalities
•	 the	Multiple	Indicator	Method
There are insufficient figures for 2006 for the latter 
method to be used. Table 3 shows the estimates for 
the three methods. The figures in the Mortality 
Multiplier have been adjusted up slightly in relation 
to previously published figures for 2003 to 2005. 
This is because the basis for the calculations from 
Statistics Norway Causes of Death Register in pre-
vious reports included too few deaths. The World 
Health Organisation (WHO) revised the coding of 
causes of death relating to drugs in 2002, and the 
changes were already implemented in the Causes of 
Death Register in Norway in 2003. This change has 
not been incorporated into our calculations until 
now. The revised figures for drug-related deaths in 
2003 to 2005 are shown in Chapter 6.1.
The trend for the number of injecting drug users 
in Norway is unchanged; the figure increased un-
til 2001, then fell until 2003 before levelling out. 
Summarising estimates from two methods, it was 
presumed that there were approximately 8,500 to 
12,500 injecting drug users in Norway in 20065.
5  The estimate has an upper limit that is higher than that result-
ing from the Multiplier Method, but lower than that resulting 
from the Multiple Indicator Method and the Municipal Survey. 
This is because the latter two methods probably produce figures 
that are too high.
4.1  Prevalence and incidence 
estimates of PDU
See the data in Standard Tables 07 and 084.
The EMCDDA defines problem use as «Injecting 
use of drugs or prolonged/regular use of opiates, 
cocaine and/or amphetamines.» In Norway, we 
only have information about the group that in-
jects drugs. The estimated number of injecting 
drug users in a given year will also include per-
sons in treatment or in prison if they inject one 
or more times during the year.
So far, we lack good data sources that can provi-
de figures for prolonged/regular use of opiates, 
cocaine and/or amphetamines. Including all ad-
missions to interdisciplinary specialised treat-
ment for drug problems in the Norwegian Pati-
ent Register will gradually provide a much better 
overview of the number of persons in this group 
who apply for and are admitted to treatment.
The number of injecting drug users in Norway is 
calculated using three methods that are descri-
bed in detail in NR 2006, Appendix 1:
4  All the Standard tables referred to have been submitted to the 
EMCDDA separately. 
Table 3: The number of injecting drug users in Norway 2002–2006. Three methods.
The Municipal Survey* The Multiple Indicator Method* The Mortality Multiplier.
2002 15,465 (12,375 – 19,001) 15,527 (11,956 – 19,098) 10,386 -14,023
2003 15,554 (13,105 – 18,575) 16,462 (15,048 – 17,876) 9,213 – 12,756
2005 17,210 (13,403 – 22,076) 14,680 (13,606 – 15,854) 8,857 – 12,400
2006 16,467 (12,830 – 19,183) - 8,524 – 11,933
* The figures for Oslo calculated using the Mortality Multiplier have also been adjusted up somewhat.
Source: SIRUS
4.  Problem drug use  
and the treatment population
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ving house and are now in treatment elsewhere. 
The data basis includes both those who were in 
treatment at the turn of the year and those who 
concluded treatment during the year. The per-
centage basis is therefore the sum of the two. The 
survey covers approx. 80 per cent of the clients, a 
slightly larger proportion than in 2006.
The average age is stable and was 40.1 years in 
2007 (2006: 39.9 years, 2005: 39.8 years). The 
same applies to the gender distribution. The pro-
portion of women was approximately 30 per cent 
in 2007, the same as in 2005 and 2006. The dif-
ferences between regions and centres are small. 
There is no indication that there are more youn-
ger clients, even though it has been made clear 
that it is permitted to admit patients younger 
than 25 (note: The formal lower age limit for ad-
mission to the programme is still 25 years).
Retention
According to the status survey for 2007, 91 per 
cent of the patients were in treatment, while 9 
per cent had been discharged. However, it is 
possible that there are a greater number of dis-
charged patients among the dropout group 
(those for whom a status form has not been 
submitted). The same type of survey for 2006 
showed 92 per cent retention. Retention is thus 
at a stable high rate, but there are moderate but 
clear differences between the centres. The dos-
age level of methadone and Subutex may be one 
of the reasons why so many remain in treat-
ment. Higher dosages are used in treatment in 
Norway than in some other countries. The av-
erage dose in 2007 was 109 mg of methadone 
per day. Two counties have an average of be-
tween 120 and 130 mg. The dosage of buprenor-
phine is unchanged or has increased slightly to 
an average of 18.6 mg in 2007.
Social function
Correspondingly, the survey shows a high pro-
portion of benefit recipients. Thirty-nine per 
cent of the patients were benefits recipients, a 
slight increase on 2006 (37 %). Seventeen per 
cent had social security as their most important 
source of income, while this proportion was 19.5 
4.2. Treatment demand indicator
Data from treatment services are still only avail-
able at aggregate level. The inclusion of all ad-
missions in the interdisciplinary specialist health 
service in the Norwegian Patient Register will 
start on 1 January 2009. It is expected that it will 
be possible to report individual-based	 data to 
EMCDDA from 2010. Overviews from the cur-
rent client mapping system run by SIRUS do not 
indicate how many individuals are included in 
the number of queries and admissions, which 
means that it is impossible to control for double 
registration. Moreover, the data basis does not 
distinguish between problem users of alcohol 
and drugs.
Several characteristics of the clients, such as gen-
der, age, education, income and most used into-
xicant, taken from the client survey in 2006, were 
presented in NR 2007, Chapter 4.2.1. Since only 
small changes take place from one year to the 
next and the data are, as mentioned, only at the 
aggregate level, this will not be discussed further 
in this report. Instead, Chapter 4.2.2 will focus 
on data and profiles for clients in medically assi-
sted treatment/rehabilitation. They are included 
in a nationwide client survey, but the probability 
of double registration is small here since most of 
them stay in the same treatment system all year.
4.2.1  Profiles of clients in medically 
assisted treatment
See also the data in Standard Table 24.
The Norwegian programme for medically assis-
ted treatment (MAT) has been discussed in pre-
vious reports to EMCDDA. See NR 2004 chapter 
5.3 in particular.
Data are reported annually in the form of status 
surveys from the 14 regional centres that make 
up the MAT programme. For 2007, a total of 
4,014 forms were completed, while 4,542 persons 
were in treatment as of 31 December 2007. A to-
tal of 562 persons had concluded treatment du-
ring the year, 32 of whom had died. Forty-six 
persons were discharged in connection with mo-
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Most centres in the Eastern Norway region, in-
cluding Oslo, score particularly high. However, 
the findings are low in the international context.
Cannabis
Almost a third have used cannabis at least once 
during the last four weeks, the same proportion 
as in 2005 and 2006.
Benzodiazepines
The use found in the survey includes both pre-
scribed benzodiazepines and illegally obtained 
benzodiazepines. The survey for 2007 shows that 
42 per cent have used such drugs in the last 
month (2006: 41%). Less than half (18%) come 
from prescriptions. Roughly one in every four 
patients has thus used illicitly acquired benzodi-
azepines. The use of this substance appears to be 
increasing. The increase is found in most of the 
centres.
Central stimulants
There is less additional misuse of such drugs. 
Nationwide, the proportion with proven use dur-
ing the past four weeks was 16 per cent, roughly 
the same as in 2006. This involves both amphet-
amine derivatives, and partly also cocaine, but 
cocaine is not checked regularly. It appears that 
the prevalence of central stimulants is greatest in 
Western Norway, where the use of buprenor-
phine in treatment is particularly high. There is 
certainly nothing to indicate that this reduces 
the use of central stimulants.
The goal of the treatment is rehabilitation. In this 
context, the survey indicates moderate success. 
While it is true that a large majority live in either 
own rented or owned housing, the proportion 
who neither have a job nor are in education is 
high, and many of them have been without work 
for years prior to MAT, while some of them have 
never been in employment. The health questions 
show that more than a quarter have a somatic ill-
ness that affects how they live their lives and their 
life quality. Since many seems to progress via re-
duced criminality and ordered finances towards 
a life on welfare benefits, this may be the most 
realistic rehabilitation goal. There are still many 
per cent in 2006, and 20 per cent in 2005. The 
proportion on medical/occupational rehabilita-
tion benefit was 40 per cent in 2007 (31.5% in 
2006 and 34% in 2005). All in all, this indicates a 
certain transition to disability benefit and slight-
ly less use of social security benefits, without this 
being the result of more active use of rehabilita-
tion. However, closer study of the pattern shows 
considerable differences between the centres.
Housing conditions
The proportion in their own rented or owned 
housing is surprisingly high, roughly eight out of 
ten in most centres. Oslo stands out with a lower 
proportion.
Health conditions
The survey’s questions about health show that 
slightly more than a quarter (27%) have a somat-
ic illness that is so serious that it affects how they 
live their lives and their life quality. There is also 
a considerable proportion with chronic infec-
tions such as HCV. Nationwide, the proportion 
of patients with HIV is three per cent. In Oslo, 
the proportion was seven per cent. In addition, 
the proportion suffering from depression and/or 
anxiety is high.
Additional misuse
The reporting was carried out by combining in-
formation about drug and alcohol use during the 
last four weeks and information from urine tests. 
Use is thus reported if there is one urine finding 
or information about at least one instance of the 
drug in question having been taken. Consider-
able uncertainty attaches to all the reports be-
cause the proportion stated as unknown is 
around 10 per cent for all the different types of 
drugs. On the other hand, there are major differ-
ences between the centres as regards the propor-
tion of unknowns.
Opioids
In 2007, the proportion of patients who had used 
a morphine-based drug in addition to the MAT 
medication during the last four weeks was 14 per 
cent for all the centres (2006: 13%). There are 
considerable differences between the centres. 
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1993. However, no new figures are available since 
this was last discussed in NR 2005 (Chapter 4.3). 
In the surveys in recent years, attempts have been 
made to map who is or has been in treatment 
during the last year in order to enable character-
istics to be described. This work continues.
whose most important source of income is social 
security benefit, but a growing proportion recei-
ve regular National Insurance benefits (Waal, 
Clausen, Håseth and Lillevold, 2008).
4.3  PDUs from non- treatment 
sources
SIRUS follows trends in the type of drugs inject-
ed and other characteristics of injecting drug us-
ers in Oslo in a continuing survey that started in 
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5.1.1 Guide to processing referrals  
to interdisciplinary specialist treatment  
for drug and/or alcohol use
In 2008, the Directorate of Health has revised a 
guide that describes the processing of referrals to 
interdisciplinary specialised treatment for drug 
and/or alcohol use. It also provides advice about 
how this can be dealt with professionally in ac-
cordance with the currently applicable profes-
sional and legal frameworks. One goal is to en-
sure equal treatment in the whole country.
The primary target group for the guide consists 
of those who assess referrals to interdisciplinary 
specialiced treatment for drug and/or alcohol 
use. In practice, this will be the bodies appointed 
by the health enterprises to carry out such as-
sessments. The guide will also be useful for social 
centres and first-line medical practitioners, as 
well as staff in the specialist health services. The 
document is not binding on service providers. 
However, the guide sets out the national health 
authorities’ views on good practice and correct 
interpretation of the regulations. If the service 
chooses a different practice than that proposed 
in the guide, it should therefore be based on a 
concrete assessment. The courts and supervisory 
authorities normally base their decisions on such 
assessments.
Pursuant to the Patients’ Rights Act, section 2–2, 
patients are entitled to an evaluation of their sta-
te of health on referral. Referrals to interdiscipli-
nary specialised treatment for drug and/or alco-
hol use can be made by the social services, the 
child welfare service, GPs, specialist physicians 
in private practice, physicians in other parts of 
the specialist health services, physicians in the 
prison health service or other health personnel 
who are entitled to refer patients to the specialist 
health service. Referrals must contain the infor-
See also information in Structured Question-
naire 27 part I: Treatment programmes and part 
II: Quality assurance.
5.1 Treatment systems
Changes in the treatment systems in Norway 
have previously been discussed in NR 2004–
2006. The evaluation of the Administrative Alco-
hol and Drugs Treatment Reform was discussed 
in NR 2007 Chapter 5.1.1. No new system chang-
es have been introduced in the treatment area.
A waiting list guarantee for children and young 
people entered into force on 1 September 2008. 
See Chapter 1.1. In connection with the amend-
ment of the law, a practice guide and a prioritisa-
tion guide are being issued that are intended to 
ensure uniform, good practise in the services.
The escalation plan for mental health (1998–
2006) and the building-up of mental health care 
for children and young people in the municipali-
ties will have consequences for the services offe-
red to children and young people who are at risk 
of developing or have developed drug and alco-
hol problems. At least 20 per cent of earmarked 
funds for the municipalities from the escalation 
plan for mental health will be used on measures 
aimed at children and young people. The muni-
cipalities shall develop low-threshold services 
for examining, treating and following up chil-
dren and young people with mental health pro-
blems, irrespective of cause and background. The 
guide to mental health care for children and 
young people in the municipalities has been 
published. It provides the municipalities with 
advice and guidance about the development of 
services for children and young people at risk 
and about the prevention of mental health pro-
blems and drug and alcohol dependency (the 
Ministry of Health and Care Services, 2008).
5. Drug-related treatment
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•	 Social	factors	with	considerable	negative	
consequences for prognoses
•	 Other	factors
The Usefulness criterion requires an assessment 
of whether the medical help from the specialist 
health service will improve the patient’s condi-
tion or prevent deterioration. Medical help in-
cludes actions that have preventive, diagnostic, 
treatment, health-preserving, rehabilitating or 
nursing and care purposes and that are carried 
out by health personnel. The main point is 
whether the medical help will lead to an im-
provement in the patient’s length of life and/or 
life quality of a certain duration or prevent dete-
rioration. Usefulness is also present if the possi-
bilities for treatment will be lost if the medical 
help is postponed. In connection with useful-
ness, it must be assessed what a relevant course 
of treatment will be for the individual patient. 
Factors that are relevant in relation to the seri-
ousness criterion should be compared with the 
following additional factors:
•	 The	desire	for	change/	commitment
•	 Experience	of	treatment
•	 Problem	use	of	short	duration
•	 Cognitive	functioning
•	 Degree	of	co-morbidity
The criterion of Cost-efficiency means that the 
costs of treatment must be in reasonable propor-
tion to the expected effects of the treatment, in 
terms of both improving the patient’s state of 
health and preventing a deterioration of his/her 
state of health. Costs incurred in connection 
with previous treatment of the same patient shall 
be disregarded. The conditions for the right to 
necessary medical help are based on the main 
conditions being interconnected and on their 
being weighted in relation to each other (the Di-
rectorate of Health, 2008).
mation that is important in terms of evaluating 
the patient’s state of health.
The main conditions for the right  
to necessary medical help
Three main conditions in the Prioritisation Reg-
ulations section 26 shall be assessed individually 
and together.
The Seriousness criterion requires an evaluation 
to be made of the patient’s condition and of how 
the patient will most probably develop if medical 
help from the specialist health service is postpo-
ned. The main topic for assessment will be the 
degree of drug and/or alcohol use and depen-
dency, and the impact the problem use can be as-
sumed to have on the patient’s expected length of 
life and life quality.
When sufficient insight has been gained into the 
patient’s condition, it shall be assessed how the 
patient’s condition will develop if medical help 
from the specialist health service is postponed in 
relation to the patient’s expected condition if 
medical help is provided. In order for the crite-
rion of seriousness to be met, it must be assumed 
to be most probable that the patient’s length of 
life will be shorter or quality of life poorer if the 
medical help is postponed than would be the si-
tuation if the patient receives the medical help. 
The following factors, which are partly linked to 
problems relating to problem use, will be rele-
vant in the assessment:
•	 Danger	to	life	and	health/self-destructiveness
•	 Suicidality
•	 Pregnancy
•	 Crises	and	serious	life	events	in	connection	
with problem use
•	 Problem	use	at	a	young	age
•	 Co-morbidity,	somatic	health
•	 Co-morbidity,	mental	health
•	 Care	and	control	of	small	children
6  Cf. the new section 4 in Regulations No 1208 of 1 December 
2000 on the prioritisation of health services, the right to neces-
sary medical help from the specialist health service, the right 
to treatment abroad and about the appeals board, amended by 
Regulations No 833 on 25 July 2008. 
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ria for admission and discharge, a requirement 
for an individual plan, follow-up teams and re-
quirements for urine testing. Professional guide-
lines and, if issued, regulations will replace the 
currently applicable circular relating to medical-
ly assisted treatment, thus helping to make medi-
cally assisted treatment a better service. The 
Ministry of Health and Care Services is said to 
be planning to present Regulations relating to 
medically assisted treatment in autumn 2008.
Based on the contents of the draft regulations 
from the Ministry, the Directorate of Health is 
working on proposals for new guidelines for the 
medically	 assisted	 treatment	 and	 rehabilitation	
of opioid addicts and guidelines for the treatment 
of pregnant women in MAT and assistance to fa-
milies up to school age. The proposals will be 
sent for consultation with a view to a decision 
being made in spring 2009.
5.2 Drug-free treatment
No major new evaluations or studies were car-
ried out in 2007.
5.3  Pharmacologically-assisted 
treatment
The evaluation of medically assisted treatment 
(see NR 2005, Chapter 5.3) shows that waiting 
times vary between the health regions. Treat-
ment and rehabilitation services vary both be-
tween and within municipalities and regions. As 
part of the follow-up of the evaluation, it has 
been decided (Proposition No 53 to the Odelst-
ing (2006–2007)) to authorise the issuing of reg-
ulations relating to medically assisted treatment. 
The regulations could include the purpose, crite-
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With effect from 1996, Statistics Norway’s figures 
have been based on EMCDDA’s definition of 
drug deaths. This broadened the inclusion crite-
rion that had been used until then. In the period 
since 1996, Statistics Norway’s figures have been 
consistently higher than the figures from Kripos. 
However, if suicide (by using drugs) and drug 
deaths among elderly people above the age of 65 
are eliminated from Statistics Norway’s statistics, 
the difference is smaller, although still conside-
rable in some years. The trends are largely identi-
cal in both series of figures, however.
6.1  Drug-related deaths and 
mortality of drug users
See the data in Standard Tables 05 and 06.
Methodological considerations
In Norway, there are two bodies that register 
drug deaths, Statistics Norway (SSB) and the Na-
tional Crime Investigation Service (Kripos). Kri-
pos bases its figures on reports from the police 
districts, while Statistics Norway prepares figures 
on the basis of medical examiners’ post-mortem 
examination reports and death certificates in ac-
cordance with the WHO’s ICD 10 codes.
Table 4: Drug-related deaths 1991–2007. Total number of deaths and broken down by gender. Figures from 
Kripos and Statistics Norway (underlying cause of death).
1991–2007
Number of deaths according to Kripos Number of deaths according to Statistics Norway
Men Women Total Men Women Total
1991 74 22 96 66 22 88
1992 78 19 97 81 23 104
1993 77 18 95 76 17 93
1994 102 22 124 105 19 124
1995 108 24 132 114 29 143
1996* 159 26 185 173 31 204
1997 149 28 177 160 34 194
1998 226 44 270 228 54 282
1999 181 39 220 191 65 256
2000 264 63 327 302 72 374
2001 286 52 338 327 78 405
2002 166 44 210 240 67 307
2003 134 38 172 174 193** 49 62** 223 255**
2004 168 55 223 171 220** 60 83** 231 303**
2005 146 38 184 142 176** 48 58** 190 234**
2006 152 43 195 187** 64** 251**
2007 162 38 200 *** *** ***
Source: Kripos and Statistics Norway
*The figures from 1996 onwards have been classified in accordance with a new revision. Hence the figures before and after 1996 are 
not directly comparable. Suicides in which narcotic substances were used are included from 1996.
** Figures based on WHO’s revised coding of causes of death.
*** Figures for 2007 are not yet available.
6. Health correlates and consequences
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reduction if we compare the same two periods. In 
the first period, the proportion was 64 per cent, 
while it was just under 59 per cent in the latter 
period (p = 0,003). The youngest age groups’ pro-
portion of deaths has remained stable during the 
period 1996 to 2006 (Figure 6).
Figure 6: Drug-related deaths broken down by age 
group, 1996–2006
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Source: SIRUS and Statistics Norway
During the period 1996 to 2006, there has been a 
certain increase in the proportion of women 
among mortalities (Figure 7). During the period 
1996 to 2000, the proportion of women was 19.5 
per cent according to the SSB statistics, while it 
had increased to 23.5 per cent in the period 2001 
to 2006 (p = 0.008). Seen in a longer perspective, 
however, this variation seems to be within the 
«normal range» for the proportion of women. 
During the period 1980 to 1990, the average pro-
portion of women among the mortalities was 
close to 22 per cent.
Figure 7: Drug-related deaths broken down by 
gender, 1996–2006
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WHO revised its coding of causes of deaths rela-
ting to drugs and alcohol in 2002. The revisions 
were implemented in the Norwegian Causes of 
Death Register as early as 2003, but they were not 
included in the Standard Tables until this year. 
The corrected figures show a higher estimate than 
previously reported by SSB. In order to highlight 
the discrepancy, both series for the period 2003–
2006 are reported in Table 4. For the three years, 
the new figures represent an average increase in 
the estimate of slightly more than 20 per cent. The 
corrected figures for 2003–2006 are now directly 
comparable with the years 1996–2002.
Situation and development
The figures from both SSB and Kripos peak in 
2000/2001. In the ensuing years, there has been a 
considerable reduction in the number of regis-
tered drug deaths. The reduction since the turn 
of the millennium is most probably due to the 
strong increase in the number of clients on med-
ically assisted treatment. Both the SSB figures 
and the Kripos figures appear to indicate that, af-
ter the reduction following the peak years of 
2000 and 2001, a certain stabilisation of the num-
ber of mortalities has occurred.
According to the statistics from Kripos for 2007, 
26 of 27 police districts had registered drug-in-
duced deaths. Oslo had most deaths (65), 33 per 
cent of the total. Very many of the deaths are be-
lieved to be due to extensive polydrug use.
In the early 1980s, the proportion of mortalities 
among those over the age of 30 was less than 20 
per cent. The proportion has increased steadily, 
and in the 1990s it had reached 60 per cent accor-
ding to SSB’s statistics. The SSB statistics show 
that, for the years 1996 to 2006, the proportion of 
drug deaths in the 30 plus age group was approxi-
mately 70 per cent on average. During the same 
period, the proportion over the age of 50 appears 
to have increased. If we compare the period 1996–
2000 with the period 2001–2006, we find that the 
proportion in the first period was approx. 5 per 
cent as opposed to more than 11 per cent in the 
latter period (p< 0.001). For the 30 to 49 age group, 
on the other hand, we find that there has been a 
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Development into AIDS has been reported in 
147 of these cases.
The incidence of HIV among injecting drug 
users in the group has remained at a stable low 
level over the last decade, with about 10 to 15 ca-
ses of HIV infection a year. The reason for this is 
not entirely clear, but a high level of testing, great 
openness regarding HIV-status within the user 
milieus, combined with a strong fear of being in-
fected and strong internal justice in the milieu, 
are assumed to be important factors. In addition, 
many of the sources of infection in the milieu 
have disappeared due to overdose deaths or been 
rehabilitated through substitution therapy or 
other forms of rehabilitation. However, the ex-
tensive outbreaks of hepatitis A and B in recent 
years, and the high incidence of hepatitis C, show 
that there is still extensive needle sharing. The 
HIV situation is therefore still unpredictable.
6.2  Drug-related  
infectious diseases
See the data in Standard Table 09.
6.2.1 HIV and AIDS
In 2007, 248 cases of HIV infection were report-
ed to the Norwegian Notification System for In-
fectious Diseases (Table 5). Thirteen of these 
cases were among injecting drug users, ten men 
and three women. The median age was 39 years 
(24 to 48 years), all of whom were men. Five of 
the drug users had been infected in Oslo. The 
number of HIV-cases remains relatively low, and 
little new infection is detected in this group.
As of 31 December 2007, a total of 541 persons 
had been diagnosed as HIV positive with injec-
ting drug use as a risk factor. This amounts to 14 
per cent of all reported cases of HIV since 1984. 
Table 5: Percentage of injecting drug users of persons infected by HIV and AIDS, with injecting risk behaviour, 
by year of diagnosis
HIV
Total
HIV injecting 
drug use
Percentage  
HIV injecting 
drug use
AIDS
total
AIDS
injecting  
drug use
Percentage 
AIDS injecting 
drug use
1984–89 894 315 35 % 142 8 6%
1990 90 22 24 % 60 13 22%
1991 142 16 11 % 57 14 25%
1992 105 12 11 % 52 8 15%
1993 113 13 12 % 63 13 21%
1994 94 13 13 % 74 19 26%
1995 105 11 10 % 67 7 10%
1996 116 9 8 % 56 11 20%
1997 114 11 10 % 35 8 23%
1998 98 8 8 % 36 4 11%
1999 147 12 7 % 31 7 23%
2000 175 7 4 % 35 5 14%
2001 157 8 5 % 33 8 24%
2002 205 16 8 % 34 4 12%
2003 238 13 5 % 53 6 11%
2004 251 15 6 % 36 4 11%
2005 219 20 9 % 32 4 13%
2006 276 7 3 % 32 4 13%
2007 248 13 5 % 11 0 0%
Total 3,787 541 14 % 939 147 16%
* The figures for some years have been corrected. The total number of new AIDS cases among injecting drug users has thus also been 
corrected. The percentage is the same, however.
Source: Norwegian Institute of Public Health
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cent of the 222 persons included in the survey 
had experienced a hepatitis A infection or been 
vaccinated against the disease, 45 per cent had 
had a hepatitis B infection and 64 per cent had 
experienced a hepatitis C infection. Forty-eight 
per cent had tags indicating that they had been 
vaccinated against hepatitis B. In Norway, hepa-
titis C is not monitored to the same extent as he-
patitis A and B, and the number of new cases of 
drug users being infected with the hepatitis C vi-
rus is therefore not known. From 1 January 2008, 
the notification criteria for hepatitis C have been 
changed, so that we can expect a better overview 
of the incidence of hepatitis C among injecting 
drug users next year.
6.3  Psychiatric co-morbidity
No new information available.
6.2.2 Hepatitis
During the nationwide outbreak of hepatitis A 
from 1996 to 2000, 1,360 drug users were identi-
fied as having acute hepatitis A. Since then, only 
sporadic, individual cases of hepatitis A have 
been reported among drug users. Since 1996, 
there has also been a considerable increase in 
hepatitis B among drug users. In 2007, 60 of a 
total of 118 reported cases of acute hepatitis B 
were among injecting drug users. During the pe-
riod 1995–2006, the total number of reported 
cases of acute hepatitis B among injecting drug 
users was 1,871.
In recent years, small-scale prevalence surveys 
have been carried out in connection with needle 
distribution in Oslo in order to register the inci-
dence of, for example, hepatitis among injecting 
drug users. These Oslo surveys are the only pre-
valence surveys that are carried out regularly 
among a representative sample of drug users in 
Norway. The 2007 survey showed that 69 per 
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7.1.1  Evaluation of the trial scheme  
for injection rooms
The City of Oslo opened an injection room on 
1 February 2005 after the Storting had passed 
a temporary act relating to a trial scheme for 
injection rooms (NR 2004 Chapter 1.1). Oslo 
is the only municipality that has made use of 
the trial scheme. The temporary act was origi-
nally intended to apply until December 2007, 
but it was subsequently prolonged by two 
years (see NR 2007 Chapter 1.1). One reason 
for the prolongation was that the trial scheme 
was under evaluation and that the Ministry of 
Health and Care Services wished to study the 
evaluation carefully before arriving at a per-
manent decision. In Chapter 1.1, an account 
is given of the Ministry’s position in relation 
to the Storting with respect to a permanent 
act. On assignment for the Ministry of Health 
and Care Services, SIRUS has evaluated the 
trial scheme in Oslo. The report became avail-
able in January 2008 (Olsen and Skretting, 
2007). Some key data and an excerpt of the 
main conclusions of the report are presented 
below.
In its first two years of operation, February 
2005 to February 2007, 409 persons were re-
gistered as users, and 383 of them used the in-
jection room on one or several occasions. Of 
the 383, 71 per cent were men and 29 per cent 
women, 23 per cent were aged 30 or younger, 
41 per cent were between 31 and 40 years old, 
and 37 per cent were older than 40.
A total of 17,226 injections took place, i.e. an 
average of 24 injections a day. There are large 
variations in terms of how often the registered 
users have used the injection room scheme. 
Only 10 per cent have used the injection room 
scheme more than six times on average per 
7.1  Prevention of  
drug-related deaths
In Structured Questionnaire 23/297, a brief 
overview is provided of the coverage rate for 
interventions that can be seen as preventing 
acute drug-related deaths, including some 
data concerning the injection room in Oslo. 
In Chapters 7.1.1 and 7.1.2, an evaluation is 
presented of two types of intervention in 
which the prevention of overdoses is one of 
several goals.
Medically assisted treatment (MAT) can un-
doubtedly be argued to be an important factor 
in the effort to prevent overdoses. The design 
of and participation in the Norwegian pro-
gramme probably contribute to reducing the 
annual number of overdose deaths to a consi-
derable extent. The MAT programme is big in 
the Norwegian context, with more than 4,500 
patients, mostly injecting drug users. Accor-
ding to the status report for 2007, some three 
per cent of the patients experienced one or 
more non-fatal overdoses during the year. 
Slightly less than two per cent have attempted 
suicide. Some of the cases are assumed to be 
overdose cases without a clear suicidal intent. 
An average level of three per cent is not unre-
asonable in a population with drug problems 
with a high incidence of depressive complain-
ts, anxiety problems and difficulties in life. 
Thirty-two individuals who were part of the 
programme died during 2007. The causes of 
death were not stated, but it must be assumed 
that several of the deaths are not due to over-
doses (Waal et al., 2008)
7  All Structured Questionnaires have been submitted to the 
EMCDDA separately. 
7.  Responses to health correlates  
and consequences
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vided. Virtually no one has any objections to 
the guidance given in connection with injec-
tions, how they are treated by staff or the 
equipment offered. The main changes they 
would like are an extension of the opening 
hours and permission to inject pills together 
with heroin. Insofar as it possible to operatio-
nalise the dignity concept, the scheme can be 
said to have contributed to increased dignity 
for the target group in question. The scheme 
can be said to have provided greater dignity 
for drug addicts in the broadest sense in that 
it recognises the need to inject drugs in a 
manner that entails as little risk as possible. 
The scheme can also be said to provide a form 
of dignity for individual users in the way that 
the users are treated by the staff.
3. Professional health and social service fol-
low-up of the users has only been registered 
in eight per cent of all visits. However, such 
follow-up is dependent on adequate staff le-
vels. Expedient premises that provide an opp-
ortunity for private conversations would also 
improve the possibilities for follow-up.
4. There is a limited basis on which to con-
clude whether the injection room scheme has 
contributed to preventing infections and the 
spread of infections. However, the users have 
to comply with clear hygiene rules. They are 
also given concrete advice about how they can 
inject in a way that causes as little harm as 
possible with respect to sores and abscesses. 
They are given guidance on injecting in 13 per 
cent of the total number of injections, and 81 
per cent of the users have received such guid-
ance on one or more occasions. It must be as-
sumed that the users take some of these «les-
sons» with them when they inject drugs 
elsewhere. Users also state that they have be-
come generally more aware of hygiene when 
they inject.
5. There are no grounds for concluding that the 
injection room scheme has contributed to a re-
duction in overdoses/overdose deaths in Oslo. If 
the scheme is to be capable of making such a 
month. Two-thirds have used the scheme two 
or fewer times a month on average during the 
period they have been registered.
Eighty per cent of the users reported injecting 
0.2 to 0.25 grams of heroin (a «quarter»). Most 
users injected in their arms (64 %). Other 
body parts used for injections were the groin 
(19%), legs (15%) and neck (2%). Only 0.6 per 
cent of all injections in the injection room re-
sulted in an overdose. Eighteen per cent of the 
users have experienced overdoses in the injec-
tion room. None of the overdoses was fatal.
Main conclusions
The target group for the injection room 
scheme is «hardcore heroin users over the age 
of 18». The aims of the trial scheme are, in 
numerical order:
1 To assess the effect of freedom from 
prosecution for the possession and use of 
drugs in a limited area.
2 To contribute to more dignity for hardcore 
drug addicts.
3 To provide a better opportunity for 
contact and dialogue between drug users 
and the help services.
4 To contribute to preventing infections and 
the spread of infections.
5 To reduce the number of overdoses and 
overdose deaths.
1. The police have loyally supported the trial 
scheme. The provision on freedom from pros-
ecution must be said to have had the effect 
that, from a legal perspective, it is practically 
possible to run an injection room scheme, 
even if it is impossible for staff to check that 
only one user dose of heroin is brought in. 
However, freedom from prosecution has also 
had the unintended effect that the possession 
of small amounts of heroin has in practice 
been further decriminalised in Oslo city cen-
tre.
2. In general, the users of the injection room 
express great satisfaction with the service pro-
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hold health services. Thirty of the services ans-
wered the first part of the questionnaire, while 
23 services answered the follow-up questionnai-
re in autumn 2007. The final report is also based 
on two survey rounds carried out at intervals of 
six months among 400 users. Moreover, a new 
user survey was conducted in which 691 users 
filled in a form, and a survey of experiences in 
the rest of the services based on focus group in-
terviews in some municipalities.
The users of the low-threshold health services 
are largely hardcore drug addicts who get high 
often and who have been drug addicts for many 
years. The average age is approximately 39 years, 
while ten per cent of the users are under the age 
of 26. The most commonly used drugs are opio-
ids, benzodiazepines, amphetamine and canna-
bis. There are many combinations of different 
drugs and many people who use combinations 
that entail a high risk. For example, 95 of 400 
users use a combination of heroin and Rohypnol 
and 80 per cent use heroin in combination with 
alcohol. Alcohol is stated to be the only intoxi-
cant by 13 users. Many of them have major health 
problems. Many have particularly serious pro-
blems relating to dental health. There are also 
very many who have problems with their mental 
health, housing situation and contact with their 
families.
Mapping twice during a six-month period provi-
ded a picture of the situation for the users over 
time. More than half the users had not experien-
ced any change that was picked up on in the qu-
estionnaire. The other half had experienced a 
change in their life situation, in either a negative 
or positive direction. Positive changes include 
users receiving treatment either in a treatment 
institution (roughly 10%) or mental health care 
(5%), being admitted to medically assisted treat-
ment (5%) or having stopped using drugs (1%). 
Negative changes include the user being in pri-
son (5%) or dying (1%).
For the users, needle distribution, dialogue/gui-
dance and nutrition are the most important rea-
contribution, it must have sufficient capacity to 
cover a substantial proportion of the total num-
ber of injections that take place.
The evaluation makes no recommendation with 
respect to whether the trial scheme should be 
made permanent. However, it points out that a 
permanent injection room scheme must involve 
setting requirements for municipalities that wish 
to establish such a service. The premises must be 
expedient and guarantee the safety of staff. Staff 
training and working conditions must also be 
better than in the trial scheme. In July 2007,the 
injection room was moved to larger and more 
suitable premises in Storgata in Oslo city centre. 
The number of users has increased and the pro-
fessional follow-up by health and social services 
seems to have improved.
7.1.2  Evaluation of low-threshold  
health services
The state gave grants to low-threshold health 
services for substance abusers in 34 municipali-
ties in 2007. The services are aimed at persons 
who use drugs particularly extensively and who 
need complex and concurrent services from dif-
ferent agencies, but who are not capable of avail-
ing themselves of ordinary health services. In the 
Government’s action plan to combat drug and 
alcohol-related problems 2003–2005 (NR 2005, 
Chapter 1), low-threshold health services are 
highlighted as important focus areas in terms of 
reducing various kinds of damage to health re-
lating to the use of drugs and alcohol, improving 
health and care services for addicts and prevent-
ing overdoses.
An evaluation was carried out of the services in 
2007. The final report became available in Janu-
ary 2008 (SINTEF, 2008). The overriding goal 
was to answer the question of whether the servi-
ces contribute to establishing an adequate service 
for drug addicts who do not use or are not 
reached by the ordinary health services.
The organisation and contents of the services 
were studied on the basis of the questionnaires 
distributed to representatives of 33 low-thres-
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7.2  Prevention and treatment of 
drug-related infectious dis-
eases
In Structured Questionnaire 23/29, a brief over-
view is provided of the coverage rate for services 
that can be regarded as preventing drug-related 
infectious diseases. No other new information is 
available.
7.3  Interventions related to  
psychiatric co-morbidity
7.3.1  National professional guidelines for 
examining, treating and following up 
persons with serious mental health 
problems and concurrent drug or 
alcohol problems.
As mentioned in NR 2007 Chapter 7.2, the Di-
rectorate of Health (formerly the Directorate for 
Health and Social Affairs) is charged with pre-
paring professional guidelines for examining, 
treating and following up persons with serious 
mental health problems and concurrent drug or 
alcohol problems. The draft, which will be dis-
tributed for consultation in autumn 2008, is ex-
pected to be implemented in spring 2009. The 
guidelines will deal with three main areas:
•	 Knowledge	about	concurrent	serious	mental	
health problems and drug and alcohol 
problems
•	 Recommended	methods	for	examination	
and diagnosis
•	 Recommended	treatment	and	other	follow-
up
The guidelines will be based on the best existing 
research and experience-based knowledge in the 
area. The different issues will be discussed and 
recommendations made to the relevant services. 
The recommendations shall be as concrete as 
possible and practicable in different situations. 
The basis for the recommendations must be doc-
umented and prioritised.
sons for using the low-threshold services. These 
are also the services most often provided to users. 
The low-threshold services provide a very wide 
range of services. In addition to health-related 
services such as improving general health, they 
include dental health and follow-up of various 
illnesses and dressing of sores, motivation to re-
duce drug use and to use ordinary services and 
the provision of general care. On the other hand, 
emergency preparedness in relation to overdo-
ses seems to be given lower priority. Only six 
services state that this is very important, while 
almost half answer that overdose emergency re-
sponse is not part of the service. These are low 
figures. The high incidence of overdoses was 
central when the state decided to earmark funds 
for low-threshold health services for drug ad-
dicts.
In the report, it is stated that, in general, the ser-
vices appear to succeed in providing good help 
for 80 per cent of the users, while 20 per cent do 
not get sufficient help for various reasons. The 
exceptions are needle distribution and condom 
distribution where few users do not get sufficient 
help. There can be many different reasons why 
help does not reach all users to the same extent. 
There are many whom it is particularly difficult 
to help because they are in a very difficult life si-
tuation in which their ability to care for 
themselves is poor, and they have difficulties 
keeping appointments with other services that 
are brought in to help users.
On the basis of the in-depth interviews with 
users, one can get the impression that low-thres-
hold services are the part of the health and social 
services that the users feel most satisfied with. A 
critical methodology comment on the results co-
uld be: The interviews were carried out in the 
premises of the low-threshold services and the 
informants knew that it was only the low-thres-
hold service, and not other services, that was to 
be evaluated. They may therefore have been more 
cautious of criticising the service because they 
are so dependent on it.
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•	 Those	who	provide	treatment/process	cases	
in the specialist health service. The 
guidelines may also be important for other 
agencies that come into contact with the 
target group.
The performance goal for the guidelines:
•	 Referrals	from	the	first	line	service	shall	as	
far as possible contain an overall assessment 
of the patient’s situation as regards both drug 
and alcohol history and mental state.
•	 The	patients’	mental	health	problem	and	
problem drug or alcohol use shall be 
examined on a broad basis.
•	 The	co-morbid	condition	shall	be	treated	at	
the same time, either by the same treatment 
entity or through cooperation with different 
entities if dual competence is not available in 
one place.
•	 Individual	plans	shall	be	prepared	that	
contribute to treatment of the patient as a 
whole.
•	 Professionals	in	mental	health	care	and	
interdisciplinary specialised drug/alcohol 
treatment must have good qualifications for 
and skills in working with this group of 
patients.
•	 The	measures	that	are	initiated	shall,	in	as	
cost-efficient a manner as possible, lead to a 
reduction in mental health symptoms and 
problem drug and alcohol use, as well as 
improving users’ life quality and functional 
level (the Directorate for Health and Social 
Affairs, 2007).
The target group of patients consists of per-
sons with serious mental health problems and 
concurrent drug or alcohol problems (dual 
diagnosis8) from the age of approximately 15 
upwards.
The definition of «serious mental health problem»:
By serious mental health problem in this context 
is meant9:
Schizophrenia and schizophrenia-like psycho-
ses, bipolar disorder, serious depressions and 
chronic long-term drug or alcohol-induced psy-
choses. Serious personality disorders such as 
schizoid, paranoid, anti-social and emotionally 
unstable personalities are included, in addition 
to serious behavioural disorders among young 
people. Some other diagnoses may be relevant if 
the problem leads to a significant loss of func-
tion, for example persons with prolonged anxi-
ety problems that are present irrespective of the 
drug and/or alcohol use.
Definition of «drug /alcohol problems»:
By drug or alcohol problems is meant addiction, 
prolonged harmful use or abuse of in toxicants 
with the exception of tobacco10. The terms drug/
alcohol problems and problem drug and alcohol 
use will be used interchangeably when discuss-
ing problems in connection with the use of in-
toxicants. Both terms include both medical and 
social consequences of problem drug and alco-
hol use and drug/alcohol problems.
The target group for the guidelines:
•	 Those	who	provide	treatment/process	cases	
in the social services and primary health 
services in the municipalities.
8  Dual diagnosis is primarily a system-related concept used to 
describe persons with serious mental health problems who 
also have a drug or alcohol problem. A broader concept is 
co-morbid condition or persons with serious mental health 
problems and drug or alcohol problems. 
9 9 In the ICD-10 diagnosis system, this means the codes F20 to 
F 29, F30, F31, F32.2, F32.3, F33.2, F33.3, F 60.0 to F 60.3, F91, 
F92.
10  ICD-10 codes F10 to F19 with the exception of F17, and «sub-
stance abuse» in DSM-IV. 
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Penal sanctions
Drug crime results in more penal sanctions than 
other types of crime. Penal sanctions for drug 
crimes have increased most during the last de-
cade and have contributed to a change in which 
groups of crime result in penal sanctions. From 
33 per cent in 1998, drug crime is now the pri-
mary offence in 41 per cent of all criminal cases. 
Eighty-seven per cent of all penal sanctions for 
crimes were imposed on people of Norwegian 
nationality, and eight per cent on people with 
European nationality. The proportion of foreign 
nationals was highest in connection with crimes 
against property and drug crimes, at 18 and 12 
per cent, respectively. See Chapter 11 Sentencing 
statistics for more information about penal sanc-
tions.
8.2.2 Driving offences
Statistics relating to driving under the influence 
are prepared by the Norwegian Institute of Public 
Health. The number of arrests in 2007 on suspi-
cion of driving under the influence of alcohol or 
8. Social correlates and consequences
8.1 Social exclusion
No new information available.
8.2 Drug-related crime
8.2.1 Drug offences
Reported drug offences
Following an increase from 2005 to 2006, the 
number of reported drug offences fell to 40,771 
in 2007 (Table 6). The number of official com-
plaints for the possession of small amounts of 
drugs (regulated in the Act relating to medicines) 
is 12 per cent lower than in 2006, and this con-
tributes most to the reduction in the number of 
reported drug offences overall. The use of drugs 
(12,806) and drug crimes pursuant to the Gen-
eral Civil Penal Code (17,779) were as frequent 
as in 2006. Thirteen hundred cases of the most 
serious type of drug crimes were registered in 
2007, slightly up on previous years.
Table 6: Number of reported drug crimes 2002–2007*
2002 2003 2004 2005 2006 2007
Drug crimes 18,047 15,009 15,671 16,163 17,966 17,779
Aggravated drug 
crimes
1,247 1,143 1,143 955 1,190 1,307
Other 545 578 501 485 568 658
Drugs, use 13,377 10,547 10,925 11,259 12,635 12, 806
Drugs,  
possession
10,930 8,533 8,364 8,070 8,627 7,562
Drugs,  
miscellaneous 
1,015 901 715 731 747 659
Total number 45,161 36,711 37,319 37,663 41,733 40,771
* Number of cases
Source: Statistics Norway.
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drugs and medicinal drugs that can be prescri-
bed (e.g. morphine and diazepam) are included. 
The analysis findings do not necessarily answer 
the question of whether or not the drug was ta-
ken illegally. As a rule, several substances were 
found in the same blood sample. The Institute of 
Public Health finds an average of three intoxica-
ting drugs per sample.
Table 7: The five most common findings of substan-
ces other than alcohol in blood samples from 
drivers arrested on suspicion of driving under the 
influence in 2007. The number and percentage of 
blood samples in which a broad analysis was 
carried out.
Name of 
substance 
Example of 
name of  
medicine
Explanation
Total 
number 
Percentage 
1 Diazepam 
Valium ® Vival 
® Stesolid ®
1,257 29%
2 THC
Active agent in 
cannabis
1,171 27%
3
Amphet-
amine
1,168 27%
4
Metham-
phetamine
914 21%
5 Clonazepam Rivotril ® 574 13%
Source: Norwegian Institute of Public Health
other substances shows little change in relation to 
previous years. The number of cases in which 
drugs and other intoxicating medicinal drugs 
were found in blood samples has remained stable 
for the last five years, at approx. 4,000 cases (Fig-
ure 8). More information and data, including 
about penal sanctions, is provided in Chapter 11.
Figure 8: The number of road traffic cases received 
involving suspicion of alcohol/other substances 
2000–2007.
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Table 7 shows which drugs/intoxicating medici-
nal drugs that were most frequently (proportion 
of more than 10%) found in blood samples of 
drivers arrested by the police in 2007 on suspici-
on of driving under the influence. The percenta-
ge shows the proportion of blood samples for 
which a broad analysis was ordered in which the 
individual substances were found. Both illicit 
Figure 9: Finds of illegal drugs in road traffic cases received 2000–2007. In numbers.
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mates (69%) had used drugs in the period prior to 
their imprisonment. Almost half of the inmates 
(45%) were what is described as «hardcore» drug 
users in the period prior to imprisonment. A 
quarter of the inmates (26%) were regular and fre-
quent injecting drug users in the period prior to 
their imprisonment. Just under a third (29 %) of 
the inmates had used drugs in connection with 
their current prison sentence. Cannabis was the 
drug most inmates reported having used. It was 
followed by amphetamine, then heroin.
The data on which the analysis is based are data 
reported by the inmates themselves. In Decem-
ber 2002, all inmates at all the 52 Norwegian pri-
sons were given a questionnaire in which they 
were asked about their demographic characte-
ristics, criminal history and use of alcohol and 
drugs.
At the time when the survey was carried out, 
there were 2,687 inmates in Norwegian prisons. 
It was estimated that between 1,700 and 1,900 of 
them had used drugs during the period prior to 
their imprisonment. Between 1,100 and 1,300 
had a serious drug problem, and between 600 
and 800 were injecting drug users.
Drug controls in prison
Regular urine sample tests are the most common 
indicator of the extent of use and of which sub-
stances are used in prisons. The National Insti-
tute of Public Health has national responsibility 
for the securing of evidence, analysis and inter-
pretation of drugs, medicines and poisons in 
samples taken from persons for whom the analy-
sis results may have consequences in criminal 
law or corresponding consequences.
Around 24,000 cases are received annually from 
the Correctional Services. Figure 10 shows an 
overview of the number of cases from prisons in 
which illegal narcotic substances or medicinal 
drugs were found. The number of such cases has 
increased from around 5,000 in recent years to 
almost 6,000 cases in 2007. Cannabis is the most 
common illicit drug. The number of cases invol-
ving amphetamine and methamphetamine con-
Cannabis
Figure 9 shows that tetrahydrocannabinol (THC) 
is one of the most frequently found substances in 
blood samples from arrested drivers. The pro-
portion of cases in which THC is found appears 
to be relatively stable at around 30 per cent of the 
samples received. Since 2002, the substance has 
been among the three most common intoxicants 
among arrested drivers. The fact that THC is 
found in a blood sample means that cannabis has 
been taken (usually smoked) shortly before the 
sample was taken, usually during the last 24 
hours.
Amphetamine/methamphetamine
In recent years, methamphetamine has been in-
creasingly found in blood samples from arrested 
drivers, while the trend for amphetamine  appears 
to be declining. This may indicate that amphet-
amine is being replaced by methamphetamine in 
some cases. Some of the methamphetamine is 
converted into amphetamine in the body. Many 
of the blood samples that contain methamphet-
amine will therefore also contain amphetamine 
even if the person in question has not necessarily 
taken both drugs. If we wish to say something 
about the use of amphetamine and methamphet-
amine combined, it is therefore misleading to 
simply add up the figures for amphetamine and 
methamphetamine.
Cocaine
The number of blood samples that tested posi-
tive for cocaine in 2007 is more or less identical 
to the figures for the two previous years. The 
body converts cocaine into the inactive metabo-
lite benzoylecgonin, a substance that does not 
have any effect. However, finding benzoylecgonin 
is definite proof that cocaine has been taken dur-
ing the previous 24 hours (Norwegian Institute 
of Public Health).
8.3 Drug use in prison
A study
A survey (Ødegård, 2008) that covered all Norwe-
gian prisons showed that two-thirds of the in-
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8.4 Social costs
No new information available. No major surveys 
or studies were carried out in 2007.
tinues to increase. Findings of methadone have 
increased most over a period of five to six years, 
and it was found in almost 1,000 cases in 2007. 
However, it is not possible to distinguish between 
lawful prescribed and illegally obtained metha-
done. Methadone-assisted treatment is approved 
in prisons as a means of rehabilitating inmates 
with an opiate addiction.
Figure 10: Drug finds in correctional service cases. In numbers 2000–2007
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In 2006, 41,484 days were served in prison pur-
suant to the Execution of Sentences Act section 
12 (alternative serving of sentences) by a total of 
439 persons. It will be assessed whether more in-
mates with drug and or alcohol problems can 
serve part of their sentences in institutions pur-
suant to section 12. Increased access to this form 
of serving of sentences is desirable. The financing 
of such measures is to be reviewed.
More units aimed at mastering drug and alcohol 
problems are to be established in Norwegian pri-
sons. In 2006, there were three units of this kind: 
in Oslo, Bergen and Trondheim. In 2007, units 
aimed at mastering drug and alcohol problems 
were established in three new prisons. The pur-
pose of the units is to improve the service to in-
mates and convicted persons who are drug ad-
dicts or alcoholics and who need treatment and 
rehabilitation. Staff at the units should have both 
health and social work and prison service back-
grounds. The treatment and rehabilitation that is 
started in prison must be followed up after rele-
ase. Steps have therefore been taken to facilitate 
good cooperation with the probation service and 
the municipal services already during the ser-
ving of sentences.
There is a particularly strong need to improve 
services to inmates during the release phase. Co-
operation between the involved parties must 
start in good time before the transition from pri-
son to freedom. Cooperation with voluntary or-
ganisations such as WayBack is important during 
this phase.
Drug programme under court control
A system of suspended sentences with a drug 
programme under court control started in 2006 
as a three-year trial scheme in Oslo and Bergen 
in order to offer convicted persons with drug or 
9.  Responses to social correlates  
and consequences
9.1 Social re-integration
No new information available.
9.2  Prevention of  
drug-related crime
9.2.1 Assistance to drug users in prison
There are many indications that services are less 
available to inmates with a drug or alcohol prob-
lem than to others. The goal of the escalation 
plan for the drugs and alcohol field (the Ministry 
of Health and Care Services, 2008) is for more 
inmates with drug or alcohol problems to be giv-
en an opportunity for better treatment and reha-
bilitation while serving prison sentences or serv-
ing sentences in other ways. This requires close 
cooperation between the prisons and the region-
al health authorities, and between the prisons 
and the municipalities.
The Ministry of Health and Care Services and 
the Ministry of Justice and the Police have pro-
duced a circular that clarifies the responsibilities, 
tasks and coordination between the municipali-
ties, the specialist health services and the Cor-
rectional Services as regards inmates and convic-
ted persons who are drug addicts/alcoholics. The 
circular is intended to improve and intensify co-
operation and ensure follow-up and continuity 
in the services. Steps will be taken to ensure that 
relevant services arrive at good solutions for co-
operation and joint plans at the regional and lo-
cal level. The need for cohesion in services befo-
re, during and after sentences are served means 
that special care services should not be develo-
ped for persons in correctional service institu-
tions.
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In 2007, 56 personal assessments were carried 
out (64 in 2006). Of these, 28 were found to be 
suitable for such a sanction. During 2007, 21 ca-
ses were concluded, one of which was disconti-
nued because of death, 19 were discontinued be-
cause of new criminality or breach of special 
conditions, and the last case was discontinued 
because the convicted person withdrew consent. 
Thirty-one new sentences were implemented in 
2007, compared with 23 in 2006 (the Correctio-
nal Services, 2008).
alcohol problems an alternative means of serving 
their sentences. The participants regularly attend 
a day centre where rehabilitation is offered by an 
inter-service team. Through this scheme, experi-
ence is being gained of inter-service cooperation 
on the follow-up of convicted persons. The trial 
scheme will be evaluated by SIRUS and then 
considered for continuation and expansion.
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use of heroin. A project has been initiated with a 
view to estimating the hidden figures for how 
much heroin there actually is on the Norwegian 
market. The project will also include the collat-
ing of interview data from interviews with in-
jecting drug users in Oslo. The aim is for the 
project to be completed and a final report pro-
duced by the end of February 2009.
10.2  Production, sources of supply 
and trafficking patterns
Most of the amphetamine and methamphetamine 
on the Norwegian market comes from illegal 
laboratories in Russia, Poland and Lithuania. 
Lithuanian criminals have had a dominant role 
for several years as suppliers of synthetic drugs 
such as amphetamine, methamphetamine and 
Rohypnol to Norway. Lithuania still has a central 
role, but the biggest quantities now come from 
the Netherlands and Poland. The main routes 
run through Germany and Denmark to the Øre-
sund Bridge and on through Sweden to Norway. 
Cars prepared with concealed cavities seems to 
be the most frequent method used.
As before, cannabis	 mostly comes to Norway 
from Morocco via two main routes – from Spain 
and Italy up to the Netherlands/Germany and on 
to Denmark and Norway. The customs service 
has uncovered large quantities of cannabis in 
passenger cars and heavy goods vehicles.
Ecstasy tablets that are sold in Norway are lar-
gely produced at illegal laboratories in the 
Netherlands and Poland. The customs service 
makes most seizures in connection with drugs 
sent by post, while the biggest seizures are made 
from cars at Norway’s borders.
Heroin comes from Pakistan and Afghanistan 
via two northerly routes via Bulgaria/Romania – 
10.1 Availability
Various factors that influence the availability of 
drugs were discussed in NR 2007 Chapter 10.1. 
No new analyses have been carried out, but the 
situation in 2007/2008 is probably fairly similar. 
In the police’s view, there are indications that co-
caine, like amphetamine and methamphetamine, 
is being distributed and used more than before. 
In a historical frame of reference, the data show 
that the proportion of cocaine seizures in rela-
tion to all other drugs has increased from ap-
prox. 0.5 per cent to four per cent in ten years.
However, the most striking development in 2007 
was the large reduction in the amount of heroin 
seized. While the number of seizures increased 
somewhat after a steady decline during the last 
six to seven years, much less heroin was seized in 
2007 than in the preceding years, eight kilos – 
compared with 93 kilos in 2006. Even though the 
quantity seized is a less reliable indicator of pre-
valence than the number of seizures, which is il-
lustrated by the fact that the quantities have va-
ried a great deal in recent years, it is nonetheless 
the case that so little heroin has not been seized 
since 1990. The reduction does not reflect availa-
bility to the same extent. The price level has re-
mained more or less unchanged, and no reports 
have been received of a heroin drought of any 
length. The low seizure figures for 2007 raise 
three questions that have yet to be answered:
•	 Has	the	supply	of	heroin	to	Norway	been	
reduced?
•	 Is	the	regular	use	of	heroin	based	on	
previously imported supplies?
•	 Is	heroin	being	imported	via	entirely	new	
routes and/or using new techniques?
The Customs Service has initiated cooperation 
with SIRUS with a view to obtaining a broader 
analysis of the drugs market with respect to the 
10. Drug markets
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Main features of the drug statistics for 2007
In 2007, 20,419 drug cases were registered and 
24,139 seizures made. The total number of cases 
and drug seizures thus declined slightly com-
pared with 2006, but there are big differences be-
tween the different types of drugs.
Such large quantities of amphetamine, methamp-
hetamine and khat have never been seized in 
Norway before, 556.7 kg amphetamine and met-
hamphetamine and more than 7.7 tonnes of 
khat.
Moreover, 95 kg of cocaine were seized in 886 
seizures. Both the quantity seized and the num-
ber of seizures indicate that the use and availabi-
lity of cocaine is on the increase.
Large seizures were also made of ecstasy (79,133 
tablets) and benzodiazepines (708,293 tablets), 
while only modest quantities of cannabis (842 
kg) and doping substances (343,000 units) were 
seized.
The amount of heroin seized in 2007 was only 
8.1 kg. Seizures of heroin only accounted for ap-
proximately five per cent of the total number of 
seizures in Norway. By comparison, this propor-
tion in 1998 was as high as 20 per cent.
While both the number of seizures and amount of 
cannabis seized declined, the cultivation of can-
nabis plants was uncovered on an extensive scale. 
During the last six months of 2007, the police un-
covered a large number of «plantations» in rented 
houses, particularly in Eastern Norway. The vast 
majority of the «gardeners», and probably also the 
ringleaders, are of Vietnamese origin.
Tendencies during the first  
six months of 2008
Large quantities of hash have been seized. Four 
hundred and one kilos were seized in one sei-
zure, the third biggest ever made in Norway. The 
large seizures involve hash that is probably pro-
duced in North Africa. As regards the number of 
seizures, it is primarily cannabis plants and mar-
ijuana that have increased substantially.
Ukraine/Russia, and then on to Poland /Lithua-
nia. Two southerly routes go through Greece/the 
Balkans to the Netherlands/Germany. From the-
re, consignments destined for Norway are sto-
wed in hand luggage or passenger cars with con-
cealed cavities.
As before, cocaine comes from South America 
to Africa and Spain and from there to the Nether-
lands and Germany before continuing up 
through Denmark to Norway. Substantial quanti-
ties are also smuggled by airline passengers who 
arrive at European airports direct from South 
America. The cocaine is smuggled on to Norway 
in many ways. The Norwegian customs service 
recently experienced a growing wave of couriers 
smuggling drugs inside their bodies at Norwegi-
an airports.
Khat is transported from production areas in 
Africa to Europe. The drug is smuggled on to 
Norway from the Netherlands and the UK by 
plane and car. Most of the seizures are made 
from airline passengers who arrive from airports 
in the Netherlands and the UK. However, the 
biggest quantities are transported by road via 
Denmark and Sweden (the customs service, per-
sonal communication).
10.3 Seizures
The data basis
The annual report from the National Criminal 
Investigation Service (Kripos) about status and 
developments in drug trafficking contains na-
tional statistics that include all seizures by the 
police, the customs service, the prisons and the 
Armed Forces. Two variables are always reported 
– the quantity seized and the number of seizures. 
The data are based on verified analysis results for 
use in ordinary criminal cases, as well as on in-
formation from the police districts when the 
drug offences are decided locally by writs with 
the option of a fine (destruction cases).
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market share of each drug based on the number 
of seizures.
Figure 11: Market share for the different drugs  
in 2007. Percentage.
Cannabis
41 % 
BZD
16 % 
Heroin
5 % 
Amph/meth-
amphetamine
22 % 
Cocaine
4 %
Ecstasy
2 % 
Other
10 %
Source: Kripos
Heroin
Only eight kilos of heroin were seized in 2007. 
Despite the small quantitites, the number of sei-
zures increased slightly compared with the two 
preceding years. The number of seizures, 4,222, 
increased slightly in 2007 after several years of 
steady decline. However, the number of seizures 
is only half the number in 2001. There are big 
For amphetamine and methamphetamine, both 
the quantities seized and the number of seizures 
remain high. The most striking seizure was of 
112.3 kilos, the biggest single seizure ever made. 
Kripos has no evidence to indicate that the im-
portation and distribution of amphetamine and 
methamphetamine has changed, and Norway is 
still seen as a substantial market for these two 
drugs in the European context.
On the basis of the seizure figures, Kripos has no 
grounds for supposing that there has been a re-
duction in the importation and use of cocaine.
For heroin, the situation has changed since 2007 
in that several large seizures have been made and 
the number of seizures is again increasing.
10.3.1  Seizures and purity of different 
types of drugs
See the data in Standard Tables 13, 14 and 15.
Table 8 shows the total number of seizures by the 
police, the customs service, prisons and the Ar-
med Forces in 2007 broken down by the most 
common types of drugs. It also shows develop-
ments in recent years and the percentage change 
since 2005. The pie chart below illustrates the 
Table 8: Number of seizures in the period 2001–2007 broken down by type of drugs*.
Drug type 2001 2002 2003 2004 2005 2006 2007
% change 
2006–2007 
Cannabis 10,838 10,921 10,397 10,066 10,128 11,221 9,953 -11.3%
Amphetamine 4,283 5,037 4,578 4,149 4,410 4,680 4,222 -9.8%
Methamphetamine 392 696 640 830 950 1,139 1,284 +12.7%
Heroin 2,501 1,906 1,709 1,390 1,151 1,087 1,204 +10.8%
Benzodiazepines 6,006 8,058 4,700 4,393 3,928 4,552 4,088 -10.2%
Painkillers/ opioids 1,109 1,237 1,216 1,179 1,319 1,161 959 -17.4%
Cocaine 496 577 504 489 685 726 908 + 25.1%
Ecstasy 837 693 405 456 341 411 421 +2.4%
Khat 198 238 249 305 210 220 376 +70.9%
LSD 52 15 31 31 34 28 14 -50%
GHB 81 75 120 28 46 65 163 +150.8%
Opium 21 14 7 18 16 23 19 -17.4%
Psilocybe mushrooms 59 66 89 77 75 82 77 -6.1%
*The figures for 2007 have been adjusted as of September 2008.
Source: Kripos
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kg of which was seized in the last six months of 
the year alone.
For hash, the average THC purity is around se-
ven per cent as it has been for many years. The 
results of measurements vary greatly, however. 
Based on the high number of hash seizures here 
in Norway, there are therefore no grounds for 
claiming that the THC content in all types of 
hash seizures has changed significantly on av-
erage. Based on the analyses carried out of can-
nabis products in recent years, it is only in some 
of the cultivation cases that the top shoots of 
cannabis plants have had high, and sometimes 
unusually high, THC values.
Amphetamine/methamphetamine
Record amounts of amphetamine and metham-
phetamine were seized in 2007, and 2006 is the 
only year in which more seizures were made than 
in 2007. A total of 559.4 kg were seized in 5,506 
seizures. Preliminary analyses show that the to-
tal seizures consist of 392 kg of amphetamine 
and 167 kg of methamphetamine. For both sub-
stances, the amounts are greater than the year 
before. Based on the number of seizures, the pro-
portion of methamphetamine is increasing sub-
stantially in relation to amphetamine. It was ap-
prox. 35 per cent in 2007. Table 9 shows 
developments in the last ten years.
All the police districts have made seizures of 
both amphetamine and methamphetamine. Six 
districts made more seizures than in 2006.
The average purity in 2007 is estimated to be 
roughly 38 per cent for amphetamine and 44 per 
cent for methamphetamine. This is somewhat lo-
wer than registered in recent years.
variations between the police districts. Heroin 
was seized in 24 of the country’s 27 police dis-
tricts and, in 14 of the districts, more seizures 
were made than in 2006.
The average purity of the heroin has increased 
from 26 per cent to 36 per cent in two years, but 
there are big variations from seizure to seizure. 
Paracetamol and caffeine, as well as other intoxi-
cating substances (benzodiazepines), are also 
found in very many seizures.
Cannabis
Since 2006, the amount of cannabis seized has 
been almost halved and the number of seizures 
has been reduced by 11 per cent. The decline in 
the number of seizures and quantities seized ap-
plies to the big towns and cities in particular. 
Even though the decline is relatively large for the 
country as a whole, nine police districts have 
made more seizures than the year before. It is a 
striking development in 2007 that the propor-
tion of marijuana and cannabis plants has in-
creased, both as regards the amount and the 
number of seizures, in relation to hash.
The amount of cannabis seized in 2007 was 863.9 
kilos. The amount consists of approx. 668 kg of 
hash (77%), 76 kg of marijuana (9%), 119.9 kg of 
cannabis plants (14%) and 0.013 kg of cannabis 
extract.
Of the total number of cannabis seizures (9,964), 
hash accounted for four-fifths. The reduction in 
the number of seizures from 2006 is more than 
17 per cent. As regards marihuana and cannabis 
plants, on the other hand, there was an increase 
of 29 per cent. In terms of quantities, the seizures 
amounted to approx. 140 kilos, as much as 119 
Table 9: Proportion of seizures of methamphetamine in relation to amphetamine 1998–2007. Percentages.
Year 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Metamph. 1.4% 1.3% 1.8% 6.2% 10.8% 15.4% 21.1% 22.0% 26.0% 35.3%
Source: Kripos
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Apart from seven minor seizures of tablets con-
taining amphetamine and equipped with an 
ecstasy logo, no other hallucinogenic, synthetic 
substances often mentioned together with ecsta-
sy were found in 2007. However, 0.86 grams of a 
powder containing 2C-B was found in four sei-
zures, and on one occasion MDEA was found in 
combination with MDMA. Neither MDA, 
MBDB, PCP, DOB, 2C-T-2, 2C-T-7, 4-MTA, 
DMT, PMA nor PMMA, all of which have been 
identified previously, were registered in any sei-
zures in 2007. On the other hand, ketamine (4.6 
grams) was found in two seizures. However, this 
substance, which is an ingredient in the Norwe-
gian-registered medicinal drug Ketalar, is not in-
cluded on the list of narcotic substances.
Benzodiazepines (BZD)
More than 730,000 seized tablets in 4,084 sei-
zures show that this class of medicinal drugs has 
in no way disappeared from the illicit market, 
even though the number of seizures has been 
halved in relation to the peak year of 2002. Dur-
ing the period 2001 to 2003, it was primarily Ro-
hypnol that dominated this class of substances 
with more than 6,500 seizures, while the figure 
five years later has fallen to roughly 800 seizures.
Based on the number of seizures parameter, it is 
diazepam that is increasing its «market share» at 
the expense of flunitrazepam. Rohypnol and Flu-
nipam were reclassified from class B to class A 
drugs with effect from 1 January 2003, and Ro-
hypnol was de-registered as a medicinal drug in 
Norway on 1 August 2004. All the Rohypnol sei-
zures must therefore come from illegal import.
Other BZD substances
Other benzodiazepines that can be mentioned in-
clude fenazepam, a benzodiazepine from Russia 
that is not in medical use in Norway. Even though 
this drug has never been very common in Nor-
way, it has nevertheless attracted a lot of attention. 
The substance was first seized in 1993 in a small 
seizure in Finnmark. There were no more seizures 
until 2003. In recent years, the prevalence of 
fenazepam appears to have been on the decline. A 
total of 2,030 tablets were seized in 2007.
Cocaine
Nine hundred and eight seizures of cocaine were 
made in 2007, the highest number of seizures of 
cocaine ever made in Norway. With the exception 
of the years 1998 and 2005, when very large quan-
tities of cocaine were seized that were not intend-
ed for the Norwegian market, 2007 was also a re-
cord year in terms of the amount seized, 95 kg.
Cocaine was seized in 26 of the country’s 27 police 
districts and 16 police districts made more seizu-
res than the year before. Oslo’s share of the cocaine 
seizures has been reduced from 62 per cent to 36 
per cent over the last 11 years, while the rest of the 
country’s share has naturally increased.
Kripos does not distinguish as a matter of routi-
ne between cocaine hydrochloride and cocaine 
base («crack»). In 2007, however, one seizure 
was made of 482 grams of a mixture of substan-
ces containing cocaine base (33–37%).
The cocaine content in the seizures has fallen stead-
ily, from more than 70 per cent 10 years ago to 38 
per cent in 2006 and 2007. Cocaine hydrochloride 
of up to 100 per cent purity was seized also in 2007. 
Fenacetine is often used as an additive.
Ecstasy
In 2007, nearly 79,000 tablets were seized in 421 
seizures. It is only in 2002 and 2003 that larger 
amounts of ecstasy have been seized than in 2007. 
The number of seizures, on the other hand, re-
mains stable. As described in previous years, it ap-
pears that the illegal traffic in ecstasy culminated 
at the turn of the millennium. However, as the sei-
zures show, ecstasy has not disappeared from the 
market. The number of seizures, however, indi-
cates that ecstasy’s market share is no greater than 
it has been for this class of substances in recent 
years. The high number of tablets seized is ex-
plained by two large seizures. Historically, they 
rank as the second and fifth biggest seizures ever.
No other substances than MDMA were found in 
the seizures in 2007.
The Drug Situation in Norway 200852
edly higher than the year before. However, only 13 
police districts (out of 27) made seizures of khat.
LSD
Based on the figures for the number of seizures, 
LSD does not appear to have become more wide-
ly available in 2007. The opposite would actually 
appear to be case. Since LSD is easy to conceal, 
however, we cannot discount the possibility that 
the seizure statistics do not truly reflect the situ-
ation.
Table 12: Amounts seized of GHB, GBL and 1.4 
butandiol 2004–2007. Litres.
2004 2005 2006 2007
GHB 3.5 litres 8.5 litres 18.2 litres 58.0 litres 
GBL 5.4 litres 0.9 litres 14.2 litres 30.4 litres 
1.4-BD 45.3 litres 7.4 litres 18.1 litres -
Source: Kripos
Khat
Khat is included on the Norwegian list of narcotic 
substances. A total of 7.747 kilos of khat was seized 
in 2007 in 376 seizures. This is a much larger 
amount and the number of seizures is also mark-
Table 11: Seizures of GHB, GBL and 1.4 butandiol 1998–2007. Number.
Substance 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
GHB 2 45 82 81 74 120 28 57 65 163
GBL - - - - 8 21 11 3 11 24
1.4-BD - - - - 17 7 24 7 10 0
Source: Kripos
Table 10: Seizures of painkillers, drug-classified medicinal drugs. Number of tablets/units and percentage.
Drug Substance % (number) of seizures Number of tablets/units 
Temgesic,Subutex Buprenorphine 45.2% (449) 4,256 tablets
Paralgin forte etc. Codeine 26.9% (267) 7,463 tablets
Dolcontin etc. Morphine 17.1% (170) 4,256 tablets
Methadone Methadone 7.8% (77) 844 units
Ketorax, Fentanyl Other 3.0% (29) 2,200 tablets
Source: Kripos
Painkillers, drug-classified medicinal drugs
A total of 17,354 tablets were seized in 959 sei-
zures. The number of seizures has thus declined 
somewhat, while the amount seized remains rel-
atively stable compared with recent years. Several 
of the cases involved illegal import of such me-
dicinal drugs via internet shopping, but the num-
ber of tablets in each seizure is relatively small. 
Based on the number of seizures, buprenorphine 
(Temgesic and Subutex) predominates, although 
the quantities seized are generally small. More 
tablets containing codeine were seized than any 
other substance.
GHB
Fifty-eight litres of GHB were seized in 163 sei-
zures in 2007. The number of seizures of GHB 
increased radically in 2007. Even if we include 
seizures of the industrial chemicals GBL and 
1.4-butandiol, substances that are not included 
on the list of narcotic substances, the figures are 
nonetheless deemed to be small compared with 
other depressants.
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10.4 Prices
See the data in Standard Table 16.
A new ‘pricelist’ for narcotic substances is availa-
ble as of October 2008. The list has been produ-
ced by Oslo police district on the basis of infor-
mation from internal police sources. Naturally, 
the prices on the illegal street market must be 
treated with considerable caution and should 
preferably also be checked against sources outsi-
de the police. Moreover, as regards large quanti-
ties, the variation in prices is particularly great 
for several of the types of drugs.
For smaller quantities, the price level seems to 
have largely remained stable for most of the ty-
pes of drugs since the last overview produced by 
the police in autumn 2006. In nominal terms, 
prices have probably fallen slightly rather than 
the opposite. The most striking development is 
that the price of cocaine appears to have fallen 
for typical sales doses. In 2006, the price for half 
a gram of cocaine was estimated to be approxi-
mately EUR 62.511 (NOK 500), while in 2008 it 
was approximately EUR 37.5 - 50 (NOK 300–
400). By comparison, the market price for heroin 
in 2008 was estimated to be EUR 62.5 (NOK 
500) for 0.5 grams and EUR 25 - 37.5 (NOK 
200–300) for 0.2 grams. Cocaine is still expensive 
in relation to amphetamine. The price level for 
one gram is more than double the price level for 
amphetamine, and the differences seem to be 
even greater for large quantities. The prices for 
ecstasy, GHB and LSD seem stable, while the 
price level for Rohypnol (per tablet, 100 mg) on 
the illegal market seems to have fallen since 
2006.
11  Conversion rate: 1 EUR=NOK 8.00
Other hallucinogenic drugs
Two hallucinogenic drugs were found for the 
first time in 2007, but neither of them is on the 
list of narcotic substances. One of them is bro-
mo-dragonfly. This substance was seized in very 
small quantities of one gram/five doses and 0.6 
grams/three doses, respectively. The other sub-
stance found was 3,4-methylenedioxymethcathi-
none or methylone in the form of 2.6 grams of 
powder.
Psychoactive plants and plant parts that are not 
classified as drugs are regularly seized on the 
grounds that their importation is not normally 
permitted. Much of this traffic is probably the re-
sult of information and offers on the internet. 
Kripos has noted in particular seeds of Argyreia 
nervosa (Hawaiian Baby Woodrose), Salvia divi-
norum, Peganum harmala, seeds of peyote cac-
tus and peyote cactus containing mescaline.
In 2005, tablets appeared containing the synthe-
tic substance 1.3-chlorphenyl piperazine, a hallu-
cinogenic that is also called mCCP. The substan-
ce, which is not yet on the list of narcotic 
substances, has no industrial or medicinal appli-
cation. The largest single seizure was made in 
Oslo in 2005, and consisted of 10,030 tablets to-
gether with 20 kilos of amphetamine. The distri-
bution of this drug has clearly been in Southern 
and Western Norway. All the tablets seized had 
the same appearance and logo as traditional 
ecstasy tablets.

PART B 
Selected issue
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In principle, the police are not entitled to decide 
a case, although informal warnings are probably 
used in some relatively trivial cases. However, 
the lower prosecuting authority is integrated 
with the police. Lawyers are employed at all the 
police stations in the country who, in addition to 
ordinary police duties, are also authorised to take 
certain decisions regarding prosecution in minor 
cases, including waiving prosecution, issuing 
writs with the option of a fine, referring to a hea-
ring by a mediation board or bringing charges 
before the courts. In the exercise of their duties 
as prosecutors, however, they are subject to the 
Director General of Public Prosecutions, not the 
Ministry of Justice and the Police.
If the prosecuting authorities bring a case before 
the courts, a number of different penal sanctions 
can be imposed. A person found guilty can be 
sentenced to pay a fine or to a prison sentence, 
which can either be unconditional or suspended 
on condition that the person in question com-
plies with certain conditions during a stipulated 
probationary period. Fines and prison sentences 
can be combined. A court can also sentence the 
offender to a community sentence, which means 
that the offender must perform certain tasks for 
a certain number of hours for the community. In 
the case of serious crimes, the offender can be 
sentenced to preventive detention if there is high 
risk of the person in question committing new, 
serious crimes.
In cases that involve drug crimes, it can be set as 
a condition for both a waiver of prosecution and 
a suspended sentence that the offender in ques-
tion refrains from using alcohol or other intoxi-
cating or narcotic substances, or undergoes tre-
atment to combat the use of such substances, in 
an institution if necessary. This latter condition 
is rarely used since it is deemed to be an inter-
vention by the court in the area of responsibility 
of the treatment sector. Normally, such a condi-
11.1  Options available in the 
country – penal sanctions  
in Norway
11.1.1 The general system of sanctions
The question of which penal sanctions are to be 
used in criminal cases in Norway is initially de-
cided by the prosecuting authorities. Instead of 
prosecuting an offender in the courts, the prose-
cuting authority can conclude the case on its 
own. One option is waiver of criminal charges, 
which means that the prosecuting authority 
waives prosecution on condition that the offend-
er in question does not reoffend during a proba-
tionary period of two years and meets any other 
requirements set by the prosecuting authority. 
The prosecuting authorities can also issue a writ 
with the option of a fine, which means that the 
offender can choose to accept the stipulated fine 
instead of having his or her case tried in the 
courts. Waiver of criminal charges was previous-
ly frequently used in less serious cases, but it is 
used relatively rarely today, also in drug cases. 
Instead, the use of writs with the option of a fine 
has increased strongly.
The prosecuting authorities also have the option 
of referring a case to a mediation board. This is 
the only form of «diversion» in Norwegian law. 
Referral to a mediation board means that the 
prosecuting authority – or, if applicable, the co-
urt as a condition for a suspended sentence – can 
transfer the case to a mediation board at which 
the offender and the victim meet and, if possible, 
agree on how the conflict between them can be 
resolved. Hearings by mediation boards are used 
in minor cases in particular, often when young 
offenders are involved. However, in cases where 
there is no victim, as in the case of driving under 
the influence of drugs or illegal association with 
drugs, a hearing by a mediation board will rarely 
be an option.
11. Sentencing statistics - Norway
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spects. If a small quantity is involved, the offence 
is punishable by fines or imprisonment for up to 
two years. Aggravated drug crimes include the 
three other degrees of gravity. If a somewhat 
larger quantity is involved, the offence is punish-
able by imprisonment for up to ten years; if a 
substantial quantity is involved, the offence is 
punishable by imprisonment for between three 
and 15 years, and under particularly aggravating 
circumstances the punishment can be up to 21 
years’ imprisonment, which is the maximum 
punishment under Norwegian criminal law after 
the repeal of life imprisonment in 1981. This 
means that drug crimes – except for driving a 
motor vehicle under the influence of drugs – fall 
into one of five categories of gravity:
1 The Act relating to medicines section 24: The 
use and possession of drugs (for own use). 
Fines or imprisonment for up to two years.
2 The General Civil Penal Code section 162 
first paragraph: Drug crimes Fines or 
imprisonment for up to two years.
3 The General Civil Penal Code section 162 
second paragraph: Aggravated drug crimes. 
Imprisonment for up to ten years.
4 The General Civil Penal Code section 162 
third paragraph first sentence: Aggravated 
drug crimes that involve a large quantity. 
Imprisonment for between three and 15 
years.
5 The General Civil Penal Code section 162 
third paragraph second sentence: Aggravated 
drug crimes that involve a very large quantity 
and where there are other particularly 
aggravating circumstances.
The General Civil Penal Code does not contain 
any provisions specifying what drugs or what 
quantities are required for the different punish-
ment alternatives to be applicable, or what other 
circumstances are to be given weight. In a circu-
lar from the Director General of Public Prosecu-
tions (Circular 1/1998 part II – Drug cases: The 
importance of quantity in the legal assessment 
and use of writs with the option of a fine), how-
ever, instructions are given for when the prose-
cuting authority shall decide cases by writs with 
tion will only be set if the person in question is 
already in treatment or has already been granted 
admission to a treatment institution at the time 
the decision to waive prosecution was made or 
the judgment was handed down. If the court 
finds that a suspended sentence cannot be impo-
sed, it will be possible to reduce the length of the 
prison sentence in many cases if the offender is a 
drug user who, since the offence, has started tre-
atment or has been assigned a place in a treat-
ment institution.
Through an amendment of the law in 1995, a sc-
heme was introduced whereby it is possible to 
impose a suspended sentence on persons with 
alcohol problems who are convicted of driving 
under the influence on condition that they un-
dergo an approved alcohol treatment program-
me under supervision of the Correctional Servi-
ces. In 2005, a trial scheme was introduced in the 
two biggest cities in Norway consisting of a drug 
programme for drug users who have been con-
victed of drug-related crimes, but this is not li-
mited to driving under the influence of drugs. 
Treatment in an institution can also be included 
as part of the programme. The programmes are 
administered by the probationary service, which 
is also responsible for following up the convicted 
offender.
11.1.2. Penal provisions for drug crimes
Minor drug offences that involve the use or pos-
session of drugs are punished pursuant to the 
Act relating to medicines (Act No 132 of 4 De-
cember 1992) section 24, for which the maxi-
mum sentence is up to two years’ imprisonment. 
Other drug crimes are punishable pursuant to 
section 162 of the General Civil Penal Code (Act 
No 10 of 22 May 1902 with subsequent amend-
ments). The General Civil Penal Code section 
162 covers all kinds of association with drugs 
other than use and possession for own use, such 
as the manufacture, importation, exportation, 
acquisition, storage, sending or conveying of 
drugs. However, the General Civil Penal Code 
section 162 distinguishes between four degrees 
of gravity depending on the drug and amount in-
volved and the nature of the offence in other re-
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11.1.3.  Penal provisions for driving  
under the influence of drugs
In Norway, the first penal provisions for driving 
motor vehicles under the influence of alcohol 
were introduced in the early 1900s. In 1936, a 
fixed limit for the blood alcohol level of 0.5 mg/
ml (which in 1988 was lowered to 0.2 mg/ml) 
was introduced, and the right to take blood sam-
ples was also introduced at the same time. Until 
1959, the law only applied to driving under the 
influence of alcohol, but from then the prohibi-
tion was extended to also cover the influence of 
«other intoxicating or narcotic substances», and 
the right to take blood samples was also extend-
ed to such cases.
However, the prohibition against driving a mo-
tor vehicle under the influence of other substan-
ces than alcohol was virtually a dormant provi-
sion for many years. Only in exceptional cases 
were blood samples examined with a view to 
establishing whether the driver had used sub-
stances other than alcohol, and in the event that 
such substances were found, there was great un-
certainty in case law about whether the driver 
could be described as being under the influence. 
The result was that hardly anyone was prosecu-
ted for driving under the influence of substances 
other than alcohol.
In 1958, the police were given the right to use a 
so-called breathalyser test on suspected drivers 
of motor vehicles with a view to establishing 
whether there was alcohol in their exhaled bre-
ath and thus grounds for taking a blood sample 
of the driver to establish guilt. However, drivers 
were not obliged to take such tests. Through an 
amendment of the law in 1981, however, the po-
lice were given the right to carry out breathalyser 
tests of drivers as a matter of routine in connec-
tion with road accidents, on suspicion of certain 
road traffic offences and in connection with or-
dinary road traffic controls. In 1988, a fixed limit 
was also introduced for punishable alcohol con-
tent in exhaled air. Because sufficiently reliable 
measuring instruments were not available, 
however, breathalyser tests were first seriously 
the option of a fine or which sentencing claims 
are to be entered in drug cases that are heard in 
the courts. In the circular, it is stipulated that in 
cases involving possession and storage where the 
aim is not resale, it shall be possible to issue writs 
with the option of a fine if the quantity does not 
exceed one to two user doses of heroin, amphet-
amine, cocaine or LSD, five grams of cannabis – 
increased to 15 grams in 2006 – five kilos of khat, 
one to two ecstasy tablets or 25 to 30 tablets con-
taining benzodiazepine.
If the case involves importation or distribution 
or exceeds these limits, the case must be brought 
to court. In such cases a claim shall be entered 
for punishment for a drug crime pursuant to the 
General Civil Penal Code section 162 first para-
graph if the case involves up to 15 grams of co-
caine or amphetamine, 350 ecstasy tablets or one 
kilo of cannabis.
If larger quantities than this are involved, a claim 
shall be entered for punishment for an aggrava-
ted drug crime pursuant to the General Civil Pe-
nal Code section 162 second paragraph if the 
case involves between approx. 15 and 750 grams 
of heroin, between approx. 50 grams and three 
kilos of amphetamine and cocaine, between ap-
prox. 350 and 15,000 user doses of LSD and 
ecstasy, or between approx. one and 80 kilos of 
cannabis. If the quantity is even greater, a claim 
shall be entered for punishment pursuant to the 
General Civil Penal Code section 162 third para-
graph first sentence. Punishment pursuant to 
section 162 third paragraph second sentence re-
quires that further aggravating circumstances 
are present.
Although the claims entered by the prosecuting 
authorities are not binding on the court, the sen-
tence will often not deviate much from the claim. 
This is due, not least, to the fact that the claim in 
an individual case – and the instructions in the 
Director General of Public Prosecutions’ circular 
– are largely based on case law from the Supreme 
Court, which has precedential effect and is the-
refore largely followed by the lower courts.
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Pursuant to section 31, the punishment for dri-
ving under the influence of alcohol varies with the 
degree of influence: a fine and a suspended prison 
sentence for a blood alcohol level of less than 1.0 
mg/ml, a fine and a suspended or unconditional 
prison sentence for a blood alcohol level of 1.0 to 
1.5 mg/ml, and a fine and unconditional prison 
sentence if the blood alcohol level is over 1.5 mg/
ml. Pursuant to the directions from the Storting 
and the Ministry of Justice and the Police, the fine 
should normally be equivalent to one and a half 
months’ gross income. For driving under the in-
fluence of substances other than alcohol, the pu-
nishment shall also vary in the same way, but be-
cause there are no corresponding units of 
measurement that can be used, the decision is left 
to the discretion of the court.
11.2. Data collection systems
11.2.1. Crime statistics
Data about crimes are published in annual crime 
statistics prepared by Statistics Norway (SSB). 
The statistics are first published on SSB’s website 
(www.ssb.no/emner/03/05) and then published 
as an annual printed publication (Crime Statis-
tics), which also contains an English text. Both 
Norwegian and English are used on the website 
and in the printed version. The crime statistics 
are available on the website one to two years, and 
in printed form two to three years, after the re-
porting year.
The crime statistics consist of police statistics 
that include all registered offences and those 
charged in these cases, sanctions statistics that 
provide information about the penal sanctions 
imposed and, finally, imprisonment statistics 
that provide information about the prison popu-
lation. The police statistics are based on the 
police’s central registration system in which all 
offences are registered, also if they have been 
committed by the same accused person. The 
sanctions statistics are based on the central cri-
minal record and police information system 
(SSP), which provides information about which 
introduced as proof of being under the influence 
of alcohol with effect from 1996.
While breathalyser tests were initially only used 
to a modest extent, their use increased as the 
1980s progressed. Even if the influence of sub-
stances other than alcohol could not be detected 
by such breathalyser tests, it could be indicated 
indirectly. If a driver appeared to be under the 
influence despite the breathalyser showing that 
he or she was not under the influence of alcohol, 
this could indicate that he or she was under the 
influence of other substances. In such case, the 
police could ensure that a blood sample was ta-
ken and that it was specially analysed with a view 
to establishing whether the person in question 
was under the influence of substances other than 
alcohol. Moreover, a gradual development took 
place on both the technical and methodological 
level as regards the chemical analyses that were 
carried out to establish the presence other such 
substances. This gradually resulted in a strong 
increase in the number of blood samples sent for 
so-called extended analysis, in which the sample 
is also analysed with a view to establishing the 
influence of substances other than alcohol. 
However, saliva samples with a view to establish-
ing whether a driver has used other substances 
are still not used by the police.12
The current penal provisions concerning driving 
under the influence of alcohol or other intoxica-
ting or narcotic substances are found in the Road 
Traffic Act sections 22 and 31. Pursuant to secti-
on 22, a driver of a motor vehicle shall be deemed 
to be under the influence in the sense of the Act 
if his or her blood alcohol level is over 0.2 mg/ml 
or more than 0.1 mg alcohol per litre air in exha-
led breath. As regards influence from other sub-
stances, on the other hand, there are no fixed li-
mits – it is up to the courts to decide whether a 
driver shall be deemed to have been under the 
influence, often by obtaining a written or oral 
statement from an expert.
12  A comprehensive test project on saliva samples was carried out 
in Norway in 2005/2006. www.fhi.no 
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sentences. The different personal data at the dif-
ferent stages of a case are presented in Table 13.
It is not possible on the basis of the crime statis-
tics to trace the same person through the diffe-
rent stages in the criminal law process. Moreover, 
registration is linked to the section or sections of 
the Penal Code that have been violated, with no 
additional description of the offence. This means 
that as regards, for example, drug offences, there 
is no information about which drugs and which 
forms of unlawful association with drugs are in-
volved, and, in the case of driving under the in-
fluence, there is no information about whether 
the person in question was under the influence 
of alcohol or another substance.
11.4 Results available
11.4.1 Statistics for drug crimes
In 2005, which is the last year for which such sta-
tistics are available, a total of 39,634 drug cases 
were investigated. Of this total, 4,487 cases were 
dropped as unsolved or because the perpetrator 
could not be held criminally liable because of his 
or her age or because of absconding. How the re-
maining 35,084 cases were decided is shown in 
Table 14.
sanctions have been imposed on those who have 
been given penal sanctions. The imprisonment 
statistics provide information about the prison 
population as of 1 January in the statistical year, 
and admissions to and departures from prisons 
during the year, and they are based on SSP, sup-
plemented by information from the Correctional 
Services’ registration system.
11.3 Data collected
In addition to the primary offence of which they 
have been found guilty, the information relating 
to persons in the crime statistics – i.e. persons 
charged, sentenced and the prison population – 
includes the primary offence they have been 
found guilty of, their gender and age, and for 
charged and sentenced persons, also their county 
of residence. For persons charged, additional in-
formation is provided about the location where 
the crime was committed (county), the number 
of offences covered by the charge and the num-
ber of accomplices, and whether the person in 
question had previous convictions during the 
last five years. For sentenced persons, informa-
tion is provided about where the crime was com-
mitted (county), nationality, the length of any 
prison sentence, the size of optional fines and 
imposed fines, in addition to the conditions set 
for waiving prosecution and suspended prison 
Table 13: Personal data at the different stages of a case
Charged* Sentenced* Prison inmates*
Number of offences
Number of accomplices
Previous convictions 
Age Age Age
Gender Gender Gender
Location of the offence (county) Location of the offence (county) 
Place of residence (county) Place of residence (county) 
Nationality
Length of prison sentence
Size of fine
Conditions for conditional sanctions
*For primary offence
Source: SIRUS
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der the influence of alcohol or other substances. 
Of these cases, 1,122 cases were dropped as un-
solved because the person in question had left 
the country, was a minor or could not be held 
criminally liable for other reasons. Of the re-
maining 7,483 cases, 451 (6.0%) were decided by 
a writ with an option of fine and 192 (2.6%) by 
waiver of prosecution, while 6,840 (91.4%) were 
prosecuted as criminal cases before the courts.
As mentioned, no information is available about 
how many of these cases involved driving under 
the influence of substances other than alcohol. 
The crime statistics do not distinguish between 
persons who are investigated for, charged with or 
sentenced for driving under the influence of al-
In 2007, a total of 14,194 sanctions were imposed 
where a drug offence was the primary offence, 
and Table 15 shows the distribution of the differ-
ent sanctions. Some of those convicted received 
a prison sentence where part of the sentence was 
suspended. They are included in the table under 
unconditional prison sentence. Moreover, some 
of the convicted persons in the table categorised 
under suspended or unconditional prison sen-
tence were also sentenced to pay a fine.
11.4.2  Statistics for driving under the 
influence of drugs
According to the police statistics for 2005, which 
is the last year for which we have data, 8,605 cas-
es were investigated that concerned driving un-
Table 14: Persons charged with drug offences 2005
General Civil Penal Code Medicines Act
Aggravated drug 
crime
Drug crime
Possession of 
drugs
Use of
drugs
Other drug 
crimes
No % No % No % No % No %
Waiving of prosecution etc. 23 2.3 1,159 7.6 881 12 876 7.6 27 49.0
Writ with option of fine 1 0.1 3,758 24.7 3,488 47.6 5,029 43.6 20 36.4
Mediation board 0 0 1 0 0 0 2 0 0 0
Charge 995 97.6 10,283 67.7 2,961 40.4 5,627 48.8 8 14.6
Total 1,019 100 15,201 100 7,330 100 11,534 100 55 100
Source: Statistics Norway, Crime Statistics
Table 15: Penal sanctions for drug offences by type of sanction 2007
General Civil Penal Code Medicines Act
Aggravated drug 
crime
Drug crime
Possession of 
drugs
Use of drugs
Other drug 
crimes
No % No % No % No % No %
Waiver of prosecution 0 0 70 .0 28 1.1 99 2.5 1 16.7
Writ with option of fine 4 0.6 4,441 63.8 2,506 94.8 3,499 88.9 4 66.7
Fine by judgment 0 0 100 1.4 60 2.3 73 1.9 1 16.7
Community sentence 63 9.7 351 5.0 4 0.2 24 0.6 0 0
Suspended prison  
sentence
20 3.1 1,172 16.8 25 0.9 86 2.2 0 0
Uncondition-al  
prison sentence
561 86.6 826 11.9 20 0.8 156 4.0 01
0
Total 648 100 6,960 99.9 2,643 100.1 3,937 100.1 6 100
Statistics Norway, Crime Statistics
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and Mørland, 2006). This means that slightly 
more than a third of all the 7,483 persons punis-
hed for driving under the influence in 2005 were 
under the influence of other substances, possibly 
in combination with alcohol.
For those drivers of motor vehicles where other 
substances are found, either in an amount that 
means they are deemed to be under the influence 
or smaller amounts, the National Institute of Pu-
blic Health provides an overview of which sub-
stances are involved. In all, 25 substances or 
groups of substances are examined, and, in many 
of the tests, several different substances are 
found.
In 2005, amphetamine was found in 1,343 blood 
samples, which is 32 per cent of all the 4,257 
samples that were subjected to extended analysis, 
and methamphetamine was found in 509 samples 
(12%). Cannabis substances were found in 1,215 
(29%) of the samples. As regards benzodiazepines, 
diazepam was found in 967 (23%) of the samples, 
clonazepam in 542 (13%), and other benzodia-
zepines were also common. Of opiates, morphine 
was found in 270 (6%) of the samples, the meta-
bolite of heroin in 117 (3%) and methadone in 
197 (5%). Cocaine was found in 142 (3%) of the 
samples and ecstasy in 63 samples (1%).
cohol and driving under the influence of other 
substances. However, there are data about sus-
pected drivers who have been subjected to a 
blood test for alcohol and an extended blood test 
(possible supplemented by a urine test) which 
are compiled by the National Institute of Public 
Health. It is the only institute in Norway that 
analyses blood samples for use in such cases, and 
data from the analyses is published annually on 
the website www.fhi.no and in the statistical pu-
blication: Alcohol and Drugs in Norway (www.
sirus.no).
According to these statistics, in 2005 a total of 
2,243 drivers of motor vehicles were proven to 
have been under the influence of alcohol through 
tests of their exhaled breath, and a blood sample 
was therefore not taken. In addition, blood 
samples were taken of a total of 6,225 drivers 
suspected of driving under the influence of alco-
hol or other substances, for 4,257 or 68 per cent 
of whom an extended analysis was carried out of 
the blood sample. There are no data about how 
many of these persons were found to be under 
the influence of substances other than alcohol, 
but estimates from the institute indicate that ap-
proximately 2,500 to 3,000 persons per year are 
found guilty of driving under the influence of 
substances other than alcohol (Christophersen 
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